118TH CONGRESS
1ST SESSION

H. R. ______

To promote price transparency in the health care sector, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

Mrs. Rodgers of Washington introduced the following bill; which was referred to the Committee on

A BILL

To promote price transparency in the health care sector, and for other purposes.

Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Lower Costs, More

Transparency Act”.

SEC. 2. TABLE OF CONTENTS.

The table of contents of this Act is as follows:

Sec. 1. Short title.
Sec. 2. Table of contents.

TITLE I—IMPROVING HEALTH CARE TRANSPARENCY
Sec. 101. Hospital price transparency.
Sec. 102. Clinical diagnostic laboratory test price transparency.
Sec. 103. Imaging price transparency.
Sec. 104. Ambulatory surgical center price transparency.
Sec. 105. Health coverage price transparency.
Sec. 106. Pharmacy benefits price transparency.
Sec. 107. Reports on health care transparency tools and data.
Sec. 108. Report on integration in Medicare.
Sec. 109. Advisory Committee.
Sec. 110. Report on impact of Medicare regulations on provider and payer consolidation.
Sec. 111. Implementation funding.

TITLE II—REDUCING HEALTH CARE COSTS FOR PATIENTS

Sec. 201. Increasing transparency in generic drug applications.
Sec. 202. Improving transparency and preventing the use of abusive spread pricing and related practices in Medicaid.
Sec. 203. Parity in Medicare payments for hospital outpatient department services furnished off-campus.
Sec. 204. Requiring a separate identification number and an attestation for each off-campus outpatient department of a provider.

TITLE III—SUPPORTING PATIENTS, HEALTH CARE WORKERS, COMMUNITY HEALTH CENTERS, AND HOSPITALS

Sec. 301. Extension for community health centers, the national health service corps, and teaching health centers that operate GME programs.
Sec. 302. Extension of special diabetes programs.
Sec. 303. Delaying certain disproportionate share hospital payment reductions under the Medicaid program.
Sec. 304. Medicaid improvement fund.

TITLE IV—INCREASING ACCESS TO QUALITY HEALTH DATA AND LOWERING HIDDEN FEES

Sec. 401. Increasing Plan Fiduciaries’ Access to Health Data.
Sec. 402. Hidden Fees Disclosure Requirements.
Sec. 403. Prescription drug price information requirement.
Sec. 404. Implementation funding.

1 TITLE I—IMPROVING HEALTH CARE TRANSPARENCY

2 SEC. 101. HOSPITAL PRICE TRANSPARENCY.

4 (a) MEDICARE.—Part E of title XVIII of the Social Security Act (42 U.S.C. 1395x et seq.) is amended by adding at the end the following new section:
“SEC. 1899C. HOSPITAL PRICE TRANSPARENCY.

“(a) Transparency Requirement.—

“(1) In general.—Beginning January 1, 2026, each specified hospital that receives payment under this title for furnishing items and services shall comply with the price transparency requirement described in paragraph (2).

“(2) Requirement described.—

“(A) In general.—For purposes of paragraph (1), the price transparency requirement described in this paragraph is, with respect to a specified hospital, that such hospital, in accordance with a method and format established by the Secretary under subparagraph (C), compile and make public (without subscription and free of charge) for each year—

“(i) all of the hospital’s standard charges (including the information described in subparagraph (B)) for each item and service furnished by such hospital;

“(ii) information in a consumer-friendly format (as specified by the Secretary)—

“(I) on the hospital’s prices (including the information described in subparagraph (B)) for as many of the
Centers for Medicare & Medicaid Services-specified shoppable services that are furnished by the hospital, and as many additional hospital-selected shoppable services (or all such additional services, if such hospital furnishes fewer than 300 shoppable services) as may be necessary for a combined total of at least 300 shoppable services; and

“(II) that includes, with respect to each Centers for Medicare & Medicaid Services-specified shoppable service that is not furnished by the hospital, an indication that such service is not so furnished; and

“(iii) an attestation that all information made public pursuant to this subparagraph is complete and accurate.

“(B) INFORMATION DESCRIBED.—For purposes of subparagraph (A), the information described in this subparagraph is, with respect to standard charges and prices, as applicable, made public by a specified hospital, the following:
“(i) A plain language description of each item or service, accompanied by, as applicable, the Healthcare Common Procedure Coding System code, the diagnosis-related group, the national drug code, or other identifier used or approved by the Centers for Medicare & Medicaid Services.

“(ii) The gross charge, as applicable, expressed as a dollar amount, for each such item or service, when provided in, as applicable, the inpatient setting and outpatient department setting.

“(iii) The discounted cash price, as applicable, expressed as a dollar amount, for each such item or service when provided in, as applicable, the inpatient setting and outpatient department setting (or, in the case no discounted cash price is available for an item or service, the median cash price charged by the hospital to self-pay individuals for such item or service when provided in such settings for the previous three years, expressed as a dollar amount, as well as, with respect to prices made public pursuant to subparagraph
(A)(ii), a link to a consumer-friendly document that clearly explains the hospital’s charity care policy that includes, if applicable, any sliding scale payment structure employed for determining charges for a self-pay individual).

“(iv) The payer-specific negotiated charges, as applicable, clearly associated with the name of the third party payer and plan and expressed as a dollar amount, that apply to each such item or service when provided in, as applicable, the inpatient setting and outpatient department setting.

“(v) The de-identified maximum and minimum negotiated charges, as applicable, for each such item or service.

“(vi) Any other additional information the Secretary may require for the purpose of improving the accuracy of, or enabling consumers to easily understand and compare, standard charges and prices for an item or service, except information that is duplicative of any other reporting requirement under this subsection.
In the case of standard charges and prices for an item or service included as part of a bundled, per diem, episodic, or other similar arrangement, the information described in this subparagraph shall be made available as determined appropriate by the Secretary.

“(C) UNIFORM METHOD AND FORMAT.—Not later than January 1, 2026, the Secretary shall establish a standard, uniform method and format for specified hospitals to use in compiling and making public standard charges pursuant to subparagraph (A)(i) and a standard, uniform method and format for such hospitals to use in compiling and making public prices pursuant to subparagraph (A)(ii). Such methods and formats—

“(i) shall, in the case of such method and format for making public standard charges pursuant to subparagraph (A)(i), ensure that such charges are made available in a machine-readable format (or a successor technology specified by the Secretary);

“(ii) may be similar to any template made available by the Centers for Medicare
& Medicaid Services as of the date of the enactment of this subparagraph;

“(iii) shall meet such standards as determined appropriate by the Secretary in order to ensure the accessibility and usability of such charges and prices; and

“(iv) shall be updated as determined appropriate by the Secretary, in consultation with stakeholders.

“(3) MONITORING COMPLIANCE.—The Secretary shall, through notice and comment rulemaking and in consultation with the Inspector General of the Department of Health and Human Services, establish a process to monitor compliance with this subsection. Such process shall ensure that each specified hospital’s compliance with this subsection is reviewed not less frequently than once every 3 years.

“(4) ENFORCEMENT.—

“(A) IN GENERAL.—In the case of a specified hospital that fails to comply with the requirements of this subsection—

“(i) not later than 30 days after the date on which the Secretary determines such failure exists, the Secretary shall sub-
mit to such hospital a notification of such
determination (which may include, as de-
termined appropriate by the Secretary, a
request for a corrective action plan to com-
ply with such requirements); and

“(ii) in the case of a hospital that
does not receive a request for a corrective
action plan as part of a notification sub-
mitted by the Secretary under clause (i)—

“(I) the Secretary shall, not later
than 45 days after such notification is
sent, determine whether such hospital
is in compliance with such require-
ments; and

“(II) if the Secretary determines
under subclause (I) that such hospital
is not in compliance with such re-
quirements, the Secretary shall ei-
ther—

“(aa) submit to such hos-
pital a request for a corrective
action plan to comply with such
requirements; or

“(bb) if the Secretary deter-
mines that such hospital has not
taken meaningful actions to come into compliance since such notification was sent, impose a civil monetary penalty in accordance with subparagraph (B).

“(B) CIVIL MONETARY PENALTY.—

“(i) IN GENERAL.—Subject to clause (vii), in addition to any other enforcement actions or penalties that may apply under another provision of law, a specified hospital that has received a request for a corrective action plan under clause (i) or (ii) of subparagraph (A) and fails to comply with the requirements of this subsection by the date that is 45 days after such request is made, and a specified hospital with respect to which the Secretary has made a determination described in clause (ii)(II)(bb) of such subparagraph, shall be subject to a civil monetary penalty of an amount specified by the Secretary for each day (beginning with the day on which the Secretary first determined that such hospital was not complying with such require-
ments) during which such failure was ongoing. Such amount shall not exceed—

“(I) in the case of a specified hospital with 30 or fewer beds, $300 per day (or, in the case of such a hospital that has been noncompliant with such requirements for a 1-year period or longer, beginning with the first day following such 1-year period, $400 per day);

“(II) in the case of a specified hospital with more than 30 beds but fewer than 101 beds, $12.50 per bed per day (or, in the case of such a hospital that has been noncompliant with such requirements for a 1-year period or longer, beginning with the first day following such 1-year period, $15 per bed per day);

“(III) in the case of a specified hospital with more than 100 beds but fewer than 201 beds, $17.50 per bed per day (or, in the case of such a hospital that has been noncompliant with such requirements for a 1-year period
or longer, beginning with the first day following such 1-year period, $20 per bed per day);

“(IV) in the case of a specified hospital with more than 200 beds but fewer than 501 beds, $20 per bed per day (or, in the case of such a hospital that has been noncompliant with such requirements for a 1-year period or longer, beginning with the first day following such 1-year period, $25 per bed per day); and

“(V) in the case of a specified hospital with more than 500 beds, $25 per bed per day (or, in the case of such a hospital that has been noncompliant with such requirements for a 1-year period or longer, beginning with the first day following such 1-year period, $35 per bed per day).

“(ii) INCREASE AUTHORITY.—In applying this subparagraph with respect to violations occurring in 2027 or a subsequent year, the Secretary may through notice and comment rulemaking increase—
“(I) the limitation on the per day amount of any penalty applicable to a specified hospital under clause (i)(I);

“(II) the limitations on the per bed per day amount of any penalty applicable under any of subclauses (II) through (V) of clause (i); and

“(III) the amounts specified in clause (iii)(II).

“(iii) PERSISTENT NONCOMPLIANCE.—

“(I) IN GENERAL.—In the case of a specified hospital (other than a specified hospital with 30 or fewer beds) that the Secretary has determined to be knowingly and willfully noncompliant with the provisions of this subsection two or more times during a 1-year period, the Secretary may increase any penalty otherwise applicable under this subparagraph by the amount specified in subclause (II) with respect to such hospital and may require such hospital to complete such
additional corrective actions plans as the Secretary may specify.

“(II) Specified amount.—For purposes of subclause (I), the amount specified in this subclause is, with respect to a specified hospital—

“(aa) with more than 30 beds but fewer than 101 beds, an amount that is not less than $500,000 and not more than $1,000,000;

“(bb) with more than 100 beds but fewer than 301 beds, an amount that is greater than $1,000,000 and not more than $2,000,000;

“(cc) with more than 300 beds but fewer than 501 beds, an amount that is greater than $2,000,000 and not more than $4,000,000; and

“(dd) with more than 500 beds, and amount that is not less than $5,000,000 and not more than $10,000,000.
“(iv) AUTHORITY TO WAIVE OR REDUCE PENALTY.—

“(I) IN GENERAL.—Subject to subclause (II), the Secretary may waive any penalty, or reduce any penalty by not more than 75 percent, otherwise applicable under this subparagraph with respect to a specified hospital located in a rural or underserved area if the Secretary certifies that imposition of such penalty would result in an immediate threat to access to care for individuals in the service area of such hospital.

“(II) LIMITATION ON APPLICATION.—The Secretary may not elect to waive a penalty under subclause (I) with respect to a specified hospital more than once in a 6-year period and may not elect to reduce such a penalty with respect to such a hospital more than once in such a period. Nothing in the preceding sentence shall be construed as prohibiting the Secretary from both waiving and reducing a
penalty with respect to a specified hospital during a 6-year period.

“(v) Provision of technical assistance.—The Secretary shall, to the extent practicable, provide technical assistance relating to compliance with the provisions of this subsection to specified hospitals requesting such assistance.

“(vi) Application of certain provisions.—The provisions of section 1128A (other than subsections (a) and (b) of such section) shall apply to a civil monetary penalty imposed under this subparagraph in the same manner as such provisions apply to a civil monetary penalty imposed under subsection (a) of such section.

“(vii) Nonduplication of certain penalties.—The Secretary may not subject a specified hospital to a civil monetary penalty under this subparagraph with respect to noncompliance with the provisions of this section for a period if the Secretary has imposed a civil monetary penalty on such hospital under section 2718(f) of the Public Health Service Act for failure to
comply with the provisions of such section for such period.

“(C) Publication of hospital price transparency information.—Beginning on January 1, 2026, the Secretary shall make publicly available on the public website of the Centers for Medicare & Medicaid Services information with respect to compliance with the requirements of this subsection and enforcement activities undertaken by the Secretary under this subsection. Such information shall be updated in real time and include—

“(i) the number of reviews of compliance with this subsection undertaken by the Secretary;

“(ii) the number of notifications described in subparagraph (A)(i) sent by the Secretary;

“(iii) the identity of each specified hospital that was sent such a notification and a description of the nature of such hospital’s noncompliance with this subsection;
“(iv) the amount of any civil monetary penalty imposed on such hospital under subparagraph (B);

“(v) whether such hospital subsequently came into compliance with this subsection;

“(vi) any waivers or reductions of penalties made pursuant to a certification by the Secretary under subparagraph (B)(iv), including—

“(I) the name of any specified hospital that received such a waiver or reduction;

“(II) the dollar amount of each such penalty so waived or reduced; and

“(III) the rationale for the granting of each such waiver or reduction; and

“(vii) any other information as determined by the Secretary.

“(b) ENSURING ACCESSIBILITY THROUGH IMPLEMENTATION.—In implementing the amendments made by this section, the Secretary of Health and Human Services shall through rulemaking ensure that a hospital submit-
ting charges and information pursuant to such amend-
ments takes reasonable steps (as specified by the Sec-
retary) to ensure the accessibility of such charges and in-
formation to individuals with limited English proficiency.
Such steps may include the hospital’s provision of inter-
pretation services or the hospital’s provision of trans-
lations of charges and information.

“(c) DEFINITIONS.—For purposes of this section:

“(1) DISCOUNTED CASH PRICE.—The term ‘dis-
counted cash price’ means the charge that applies to
an individual who pays cash, or cash equivalent, for
an item or service.

“(2) FEDERAL HEALTH CARE PROGRAM.—The
term ‘Federal health care program’ has the meaning
given such term in section 1128B.

“(3) GROSS CHARGE.—The term ‘gross charge’
means the charge for an individual item or service
that is reflected on a specified hospital’s or provider
of service’s or supplier’s, as applicable, chargemaster, absent any discounts.

“(4) GROUP HEALTH PLAN; GROUP HEALTH IN-
surance coverage; INDIVIDUAL HEALTH INSUR-
ANCE COVERAGE.—The terms ‘group health plan’,
‘group health insurance coverage’, and ‘individual
health insurance coverage’ have the meaning given
such terms in section 2791 of the Public Health Service Act.

“(5) PAYER-SPECIFIC NEGOTIATED CHARGE.—
The term ‘payer-specific negotiated charge’ means the charge that a specified hospital or provider of services or supplier, as applicable, has negotiated with a third party payer for an item or service.

“(6) SHOPPABLE SERVICE.—The term ‘shoppable service’ means a service that can be scheduled by a health care consumer in advance and includes all ancillary items and services customarily furnished as part of such service.

“(7) SPECIFIED HOSPITAL.—The term ‘specified hospital’ means a hospital (as defined in section 1861(e)), a critical access hospital (as defined in section 1861(mmm)(1)), or a rural emergency hospital (as defined in section 1861(kkk)).

“(8) THIRD PARTY PAYER.—The term ‘third party payer’ means an entity that is, by statute, contract, or agreement, legally responsible for payment of a claim for a health care item or service.”.

(b) PHSA.—

(1) IN GENERAL.—Section 2718 of the Public Health Service Act (42 U.S.C. 300gg–18) is amend-
ed by adding at the end the following new sub-
section:

“(f) HOSPITAL TRANSPARENCY REQUIREMENT.—

“(1) IN GENERAL.—Beginning January 1, 2026, each hospital shall comply with the price transparency requirement described in paragraph (2).

“(2) REQUIREMENT DESCRIBED.—

“(A) IN GENERAL.—For purposes of paragraph (1), the price transparency requirement described in this paragraph is, with respect to a hospital, that such hospital, in accordance with a method and format established by the Secretary under subparagraph (C), compile and make public (without subscription and free of charge) for each year—

“(i) all of the hospital’s standard charges (including the information described in subparagraph (B)) for each item and service furnished by such hospital;

“(ii) information in a consumer-friendly format (as specified by the Secretary)—

“(I) on the hospital’s prices (in-
subparagraph (B)) for as many of the
Centers for Medicare & Medicaid
Services-specified shoppable services
that are furnished by the hospital,
and as many additional hospital-se-
lected shoppable services (or all such
additional services, if such hospital
furnishes fewer than 300 shoppable
services) as may be necessary for a
combined total of at least 300
shoppable services; and

“(II) that includes, with respect
to each Centers for Medicare & Med-
icaid Services-specified shoppable
service that is not furnished by the
hospital, an indication that such serv-
vice is not so furnished; and

“(iii) an attestation that all informa-
tion made public pursuant to this subpara-
graph is complete and accurate.

“(B) INFORMATION DESCRIBED.—For pur-
poses of subparagraph (A), the information de-
dcribed in this subparagraph is, with respect to
standard charges and prices, as applicable,
made public by a hospital, the following:
“(i) A plain language description of each item or service, accompanied by, as applicable, the Healthcare Common Procedure Coding System code, the diagnosis-related group, the national drug code, current procedure terminology codes, or other identifier used or approved by the Centers for Medicare & Medicaid Services.

“(ii) The gross charge, as applicable, expressed as a dollar amount, for each such item or service, when provided in, as applicable, the inpatient setting and outpatient department setting.

“(iii) The discounted cash price, as applicable, expressed as a dollar amount, for each such item or service when provided in, as applicable, the inpatient setting and outpatient department setting (or, in the case no discounted cash price is available for an item or service, the median cash price charged by the hospital to self-pay individuals for such item or service when provided in such settings for the previous three years, expressed as a dollar amount, as well as, with respect to prices
made public pursuant to subparagraph (A)(ii), a link to a consumer-friendly document that clearly explains the hospital’s charity care policy that includes, if applicable, any sliding scale payment structure employed for determining charges for a self-pay individual).

“(iv) The payer-specific negotiated charges, as applicable, clearly associated with the name of the third party payer and plan and expressed as a dollar amount, that apply to each such item or service when provided in, as applicable, the inpatient setting and outpatient department setting.

“(v) The de-identified maximum and minimum negotiated charges, as applicable, for each such item or service.

“(vi) Any other additional information the Secretary may require for the purpose of improving the accuracy of, or enabling consumers to easily understand and compare, standard charges and prices for an item or service, except information that is
duplicative of any other reporting requirement under this subsection.

In the case of standard charges and prices for an item or service included as part of a bundled, per diem, episodic, or other similar arrangement, the information described in this subparagraph shall be made available as determined appropriate by the Secretary.

“(C) Uniform method and format.—Not later than January 1, 2026, the Secretary shall establish a standard, uniform method and format for hospitals to use in compiling and making public standard charges pursuant to subparagraph (A)(i) and a standard, uniform method and format for such hospitals to use in compiling and making public prices pursuant to subparagraph (A)(ii). Such methods and formats—

“(i) shall, in the case of such method and format for making public standard charges pursuant to subparagraph (A)(i), ensure that such charges are made available in a machine-readable format (or a successor technology specified by the Secretary);
“(ii) may be similar to any template made available by the Centers for Medicare & Medicaid Services as of the date of the enactment of this subparagraph;

“(iii) shall meet such standards as determined appropriate by the Secretary in order to ensure the accessibility and usability of such charges and prices; and

“(iv) shall be updated as determined appropriate by the Secretary, in consultation with stakeholders.

“(3) MONITORING COMPLIANCE.—The Secretary shall, through notice and comment rule-making and in consultation with the Inspector General of the Department of Health and Human Services, establish a process to monitor compliance with this subsection. Such process shall ensure that each hospital’s compliance with this subsection is reviewed not less frequently than once every 3 years.

“(4) ENFORCEMENT.—

“(A) IN GENERAL.—In the case of a hospital that fails to comply with the requirements of this subsection—

“(i) not later than 30 days after the date on which the Secretary determines
such failure exists, the Secretary shall submit to such hospital a notification of such
determination (which may include, as determined appropriate by the Secretary, a request for a corrective action plan to comply with such requirements); and

“(ii) in the case of a hospital that does not receive a request for a corrective action plan as part of a notification submitted by the Secretary under clause (i)—

“(I) the Secretary shall, not later than 45 days after such notification is sent, determine whether such hospital is in compliance with such requirements; and

“(II) if the Secretary determines under subclause (I) that such hospital is not in compliance with such requirements, the Secretary shall either—

“(aa) submit to such hospital a request for a corrective action plan to comply with such requirements; or
“(bb) if the Secretary determines that such hospital has not taken meaningful actions to come into compliance since such notification was sent, impose a civil monetary penalty in accordance with subparagraph (B)).

“(B) CIVIL MONETARY PENALTY.—

“(i) IN GENERAL.—In addition to any other enforcement actions or penalties that may apply under another provision of law, a hospital that has received a request for a corrective action plan under clause (i) or (ii) of subparagraph (A) and fails to comply with the requirements of this subsection by the date that is 45 days after such request is made, and a hospital with respect to which the Secretary has made a determination described in clause (ii)(II)(bb) of such subparagraph, shall be subject to a civil monetary penalty of an amount specified by the Secretary for each day (beginning with the day on which the Secretary first determined that such hospital was not complying with such require-
ments) during which such failure was on-
going. Such amount shall not exceed—

“(I) in the case of a hospital with
30 or fewer beds, $300 per day (or, in
the case of such a hospital that has
been noncompliant with such require-
ments for a 1-year period or longer,
beginning with the first day following
such 1-year period, $400 per bed per
day);

“(II) in the case of a hospital
with more than 30 beds but fewer
than 101 beds, $12.50 per bed per
day (or, in the case of such a hospital
that has been noncompliant with such
requirements for a 1-year period or
longer, beginning with the first day
following such 1-year period, $15 per
bed per day);

“(III) in the case of a hospital
with more than 100 beds but fewer
than 201 beds, $17.50 per bed per
day (or, in the case of such a hospital
that has been noncompliant with such
requirements for a 1-year period or
longer, beginning with the first day following such 1-year period, $20 per bed per day);

“(IV) in the case of a hospital with more than 200 beds but fewer than 501 beds, $20 per bed per day (or, in the case of such a hospital that has been noncompliant with such requirements for a 1-year period or longer, beginning with the first day following such 1-year period, $25 per bed per day); and

“(V) in the case of a hospital with more than 500 beds, $25 per bed per day (or, in the case of such a hospital that has been noncompliant with such requirements for a 1-year period or longer, beginning with the first day following such 1-year period, $35 per bed per day).

“(ii) INCREASE AUTHORITY.—In applying this subparagraph with respect to violations occurring in 2027 or a subsequent year, the Secretary may through notice and comment rulemaking increase—
“(I) the limitation on the per day amount of any penalty applicable to a hospital under clause (i)(I);

“(II) the limitations on the per bed per day amount of any penalty applicable under any of subclauses (II) through (V) of clause (i); and

“(III) the amounts specified in clause (iii)(II).

“(iii) PERSISTENT NONCOMPLIANCE.—

“(I) IN GENERAL.—In the case of a hospital (other than a hospital with 30 or fewer beds) that the Secretary has determined to be knowingly and willfully noncompliant with the provisions of this subsection two or more times during a 1-year period, the Secretary may increase any penalty otherwise applicable under this subparagraph by the amount specified in subclause (II) with respect to such hospital and may require such hospital to complete such additional cor-
rective actions plans as the Secretary may specify.

“(II) SPECIFIED AMOUNT.—For purposes of subclause (I), the amount specified in this subclause is, with respect to a hospital—

“(aa) with more than 30 beds but fewer than 101 beds, an amount that is not less than $500,000 and not more than $1,000,000;

“(bb) with more than 100 beds but fewer than 301 beds, an amount that is greater than $1,000,000 and not more than $2,000,000;

“(cc) with more than 300 beds but fewer than 501 beds, an amount that is greater than $2,000,000 and not more than $4,000,000; and

“(dd) with more than 500 beds, and amount that is not less than $5,000,000 and not more than $10,000,000.
“(iv) Authority to waive or reduce penalty.—

“(I) In general.—Subject to subclause (II), the Secretary may waive any penalty, or reduce any penalty by not more than 75 percent, otherwise applicable under this subparagraph with respect to a hospital located in a rural or underserved area if the Secretary certifies that imposition of such penalty would result in an immediate threat to access to care for individuals in the service area of such hospital.

“(II) Limitation on application.—The Secretary may not elect to waive a penalty under subclause (I) with respect to a hospital more than once in a 6-year period and may not elect to reduce such a penalty with respect to such a hospital more than once in such a period. Nothing in the preceding sentence shall be construed as prohibiting the Secretary from both waiving and reducing a penalty with
respect to a hospital during a 6-year period.

“(v) Provision of technical assistance.—The Secretary shall, to the extent practicable, provide technical assistance relating to compliance with the provisions of this section to hospitals requesting such assistance.

“(vi) Application of certain provisions.—The provisions of section 1128A (other than subsections (a) and (b) of such section) shall apply to a civil monetary penalty imposed under this subparagraph in the same manner as such provisions apply to a civil monetary penalty imposed under subsection (a) of such section.

“(vii) Nonduplication of penalties.—The Secretary may not subject a hospital to a civil monetary penalty under this subparagraph with respect to non-compliance with the provisions of this subsection for a period if the Secretary has imposed a civil monetary penalty on such hospital under section 1899C of the Social
Security Act for failure to comply with the provisions of such section for such period.

“(C) Publication of hospital price transparency information.—Beginning on January 1, 2026, the Secretary shall make publicly available on the public website of the Centers for Medicare & Medicaid Services information with respect to compliance with the requirements of this subsection and enforcement activities undertaken by the Secretary under this subsection. Such information shall be updated in real time and include—

“(i) the number of reviews of compliance with this subsection undertaken by the Secretary;

“(ii) the number of notifications described in subparagraph (A)(i) sent by the Secretary;

“(iii) the identity of each hospital that was sent such a notification and a description of the nature of such hospital’s non-compliance with this subsection;

“(iv) the amount of any civil monetary penalty imposed on such hospital under subparagraph (B);
“(v) whether such hospital subsequently came into compliance with this subsection;

“(vi) any waivers or reductions of penalties made pursuant to a certification by the Secretary under subparagraph (B)(iv), including—

“(I) the name of any hospital that received such a waiver or reduction;

“(II) the dollar amount of each such penalty so waived or reduced; and

“(III) the rationale for the granting of each such waiver or reduction; and

“(vii) any other information as determined by the Secretary.

“(5) Ensuring accessibility through implementation.—In implementing the amendments made by this section, the Secretary of Health and Human Services shall through rulemaking ensure that a hospital submitting charges and information pursuant to such amendments takes reasonable steps (as specified by the Secretary) to ensure the
accessibility of such charges and information to individuals with limited English proficiency. Such steps may include the hospital’s provision of interpretation services or the hospital’s provision of translations of charges and information.

“(6) DEFINITIONS.—For purposes of this subsection:

“(A) DISCOUNTED CASH PRICE.—The term ‘discounted cash price’ means the charge that applies to an individual who pays cash, or cash equivalent, for a hospital-furnished item or service.

“(B) FEDERAL HEALTH CARE PROGRAM.—The term ‘Federal health care program’ has the meaning given such term in section 1128B of the Social Security Act.

“(C) GROSS CHARGE.—The term ‘gross charge’ means the charge for an individual item or service that is reflected on a hospital’s chargemaster, absent any discounts.

“(D) PAYER-SPECIFIC NEGOTIATED CHARGE.—The term ‘payer-specific negotiated charge’ means the charge that a hospital has negotiated with a third party payer for an item or service.
“(E) SHOPPABLE SERVICE.—The term ‘shoppable service’ means a service that can be scheduled by a health care consumer in advance and includes all ancillary items and services customarily furnished as part of such service.

“(F) THIRD PARTY PAYER.—The term ‘third party payer’ means an entity that is, by statute, contract, or agreement, legally responsible for payment of a claim for a health care item or service.”.

(2) CONFORMING AMENDMENTS.—Section 2718 of the Public Health Service Act (42 U.S.C. 300gg–18) is amended—

(A) in subsection (b)(3), by inserting “(other than the provisions of subsection (f))” after “this section”; and

(B) in subsection (e), by adding at the end the following new sentence: “The preceding provisions of this subsection shall not apply beginning on January 1, 2026.”.

(3) EFFECTIVE DATE.—The amendments made by this subsection shall apply beginning January 1, 2026.

(c) ACCESSIBILITY THROUGH IMPLEMENTATION.—In implementing the amendments made by this section,
the Secretary of Health and Human Services shall through rulemaking ensure that a hospital submitting charges and information pursuant to such amendments takes reasonable steps (as specified by the Secretary) to ensure the accessibility of such charges and information to individuals with limited English proficiency. Such steps may include the hospital’s provision of interpretation services or the hospital’s provision of translations of charges and information.

SEC. 102. CLINICAL DIAGNOSTIC LABORATORY TEST PRICE TRANSPARENCY.

Section 1846 of the Social Security Act (42 U.S.C. 1395w–2) is amended—

(1) in the header, by inserting “AND ADDITIONAL REQUIREMENTS” after “SANCTIONS”; and

(2) by adding at the end the following new subsection:

“(c) Price Transparency Requirement.—

“(1) IN GENERAL.—Beginning January 1, 2026, any applicable laboratory that receives payment under this title for furnishing any specified clinical diagnostic laboratory test under this title shall—
“(A) make publicly available on an Internet website the information described in paragraph (2) with respect to each such specified clinical diagnostic laboratory test that such laboratory so furnishes; and

“(B) ensure that such information is updated not less frequently than annually.

“(2) INFORMATION DESCRIBED.—For purposes of paragraph (1), the information described in this paragraph is, with respect to an applicable laboratory and a specified clinical diagnostic laboratory test, the following:

“(A) The discounted cash price for such test (or, if no such price exists, the gross charge for such test).

“(B) The deidentified minimum payer-specific negotiated charge for such test.

“(C) The deidentified maximum payer-specific negotiated charge between such laboratory and any third party payer for such test.

“(3) UNIFORM METHOD AND FORMAT.—Not later than January 1, 2026, the Secretary shall establish a standard, uniform method and format for applicable laboratories to use in compiling and mak-
ing public information pursuant to paragraph (1).

Such method and format—

“(A) may be similar to any template made available by the Centers for Medicare & Medicaid Services (as described in section 1899C(a)(2)(C)(ii));

“(B) shall meet such standards as determined appropriate by the Secretary in order to ensure the accessibility and usability of such information; and

“(C) shall be updated as determined appropriate by the Secretary, in consultation with stakeholders.

“(4) INCLUSION OF ANCILLARY SERVICES.—

Any price or rate for a specified clinical diagnostic laboratory test available to be furnished by an applicable laboratory made publicly available in accordance with paragraph (1) shall include the price or rate (as applicable) for any ancillary item or service (such as specimen collection services) that would normally be furnished by such laboratory as part of such test, as specified by the Secretary.

“(5) ENFORCEMENT.—
“(A) IN GENERAL.—In the case that the Secretary determines that an applicable laboratory is not in compliance with paragraph (1)—

“(i) not later than 30 days after such determination, the Secretary shall notify such laboratory of such determination; and

“(ii) if such laboratory continues to fail to comply with such paragraph after the date that is 90 days after such notification is sent, the Secretary may impose a civil monetary penalty in an amount not to exceed $300 for each (beginning with the day on which the Secretary first determined that such laboratory was failing to comply with such paragraph) during which such failure is ongoing.

“(B) INCREASE AUTHORITY.—In applying this paragraph with respect to violations occurring in 2027 or a subsequent year, the Secretary may through notice and comment rule-making increase the per day limitation on civil monetary penalties under subparagraph (A)(ii).

“(C) APPLICATION OF CERTAIN PROVISIONS.—The provisions of section 1128A (other than subsections (a) and (b) of such section)
shall apply to a civil monetary penalty imposed
under this paragraph in the same manner as
such provisions apply to a civil monetary pen-
alty imposed under subsection (a) of such sec-
tion.

“(6) Provision of technical assistance.—
The Secretary shall, to the extent practicable, pro-
vide technical assistance relating to compliance with
the provisions of this subsection to applicable labora-
tories requesting such assistance.

“(7) Definitions.—In this subsection:

“(A) Applicable laboratory.—The
term ‘applicable laboratory’ has the meaning
given such term in section 414.502, of title 42,
Code of Federal Regulations (or a successor
regulation), except that such term does not in-
clude a laboratory with respect to which stand-
ard charges and prices for specified clinical di-
agnostic laboratory tests furnished by such lab-
oratory are made available by a hospital pursu-
ant to section 1899C or section 2718(f) of the
Public Health Service Act.

“(B) Discounted cash price.—The
term ‘discounted cash price’ means the charge
that applies to an individual who pays cash, or cash equivalent, for an item or service.

“(C) Gross charge.—The term ‘gross charge’ means the charge for an individual item or service that is reflected on an applicable laboratory’s chargemaster, absent any discounts.

“(D) Payer-specific negotiated charge.—The term ‘payer-specific negotiated charge’ means the charge that an applicable laboratory has negotiated with a third party payer for an item or service.

“(E) Specified clinical diagnostic laboratory test.—The term ‘specified clinical diagnostic laboratory test’ means a clinical diagnostic laboratory test that is included on the list of shoppable services specified by the Centers for Medicare & Medicaid Services (as described in section 1899C(a)(2)(A)(ii)(I)), other than such a test that is only available to be furnished by a single provider of services or supplier.

“(F) Third party payer.—The term ‘third party payer’ means an entity that is, by statute, contract, or agreement, legally respon-
sible for payment of a claim for a health care item or service.”

SEC. 103. IMAGING PRICE TRANSPARENCY.

Section 1899C of the Social Security Act, as added by section 101, is amended—

(1) by redesignating subsection (b) as subsection (c);

(2) by inserting after subsection (a) the following new subsection:

“(b) IMAGING SERVICES PRICE TRANSPARENCY.—

“(1) In general.—Beginning January 1, 2028, each provider of services and supplier that receives payment under this title for furnishing a specified imaging service, other than such a provider or supplier with respect to which standard charges and prices for such services furnished by such provider or supplier are made available by a hospital pursuant to section 1899C or section 2718(f) of the Public Health Service Act, shall—

“(A) make publicly available (in accordance with paragraph (3)) on an Internet website the information described in paragraph (2) with respect to each such service that such provider of services or supplier furnishes; and
“(B) ensure that such information is updated not less frequently than annually.

“(2) INFORMATION DESCRIBED.—For purposes of paragraph (1), the information described in this paragraph is, with respect to a provider of services or supplier and a specified imaging service, the following:

“(A) The discounted cash price for such service (or, if no such price exists, the gross charge for such service).

“(B) If required by the Secretary, the deidentified minimum payer-specific negotiated charge for such service and the deidentified maximum payer-specific negotiated charge for such service.

“(3) UNIFORM METHOD AND FORMAT.—Not later than January 1, 2028, the Secretary shall establish a standard, uniform method and format for providers of services and suppliers to use in making public information described in paragraph (2). Any such method and format—

“(A) may be similar to any template made available by the Centers for Medicare & Medicaid Services (as described in section 1899C(a)(2)(C)(ii));
“(B) shall meet such standards as determined appropriate by the Secretary in order to ensure the accessibility and usability of such information; and

“(C) shall be updated as determined appropriate by the Secretary, in consultation with stakeholders.

“(4) Monitoring Compliance.—The Secretary shall, through notice and comment rulemaking and in consultation with the Inspector General of the Department of Health and Human Services, establish a process to monitor compliance with this subsection.

“(5) Enforcement.—

“(A) In General.—In the case that the Secretary determines that a provider of services or supplier is not in compliance with paragraph (1)—

“(i) not later than 30 days after such determination, the Secretary shall notify such provider or supplier of such determination;

“(ii) upon request of the Secretary, such provider or supplier shall submit to the Secretary, not later than 45 days after
the date of such request, a corrective action plan to comply with such paragraph; and

“(iii) if such provider or supplier continues to fail to comply with such paragraph after the date that is 90 days after such notification is sent (or, in the case of such a provider or supplier that has submitted a corrective action plan described in clause (ii) in response to a request so described, after the date that is 90 days after such submission), the Secretary may impose a civil monetary penalty in an amount not to exceed $300 for each day (beginning with the day on which the Secretary first determined that such provider or supplier was failing to comply with such paragraph) during which such failure to comply or failure to submit is ongoing.

“(B) INCREASE AUTHORITY.—In applying this paragraph with respect to violations occurring in 2029 or a subsequent year, the Secretary may through notice and comment rule-making increase the amount of the civil monetary penalty under subparagraph (A)(iii).
“(C) Application of Certain Provisions.—The provisions of section 1128A (other than subsections (a) and (b) of such section) shall apply to a civil monetary penalty imposed under this paragraph in the same manner as such provisions apply to a civil monetary penalty imposed under subsection (a) of such section.

“(D) Authority to Waive or Reduce Penalty.—

“(i) In General.—Subject to clause (ii), the Secretary may waive or reduce any penalty otherwise applicable with respect to a provider of services or supplier under this subparagraph if the Secretary certifies that imposition of such penalty would result in an immediate threat to access to care for individuals in the service area of such provider or supplier.

“(ii) Limitation.—The Secretary may not elect to waive or reduce a penalty under clause (i) with respect to a specific provider of services or supplier more than 3 times.
“(E) **PROVISION OF TECHNICAL ASSISTANCE.**—The Secretary shall, to the extent practicable, provide technical assistance relating to compliance with the provisions of this subsection to providers of services and suppliers requesting such assistance.

“(F) **CLARIFICATION OF NONAPPLICABILITY OF OTHER ENFORCEMENT PROVISIONS.**—Notwithstanding any other provision of this title, this paragraph shall be the sole means of enforcing the provisions of this subsection.”; and

(3) in subsection (c), as so redesignated by paragraph (1)—

(A) by redesignating paragraph (8) as paragraph (9); and

(B) by inserting after paragraph (7) the following new paragraph:

“(8) **SPECIFIED IMAGING SERVICE.**—the term ‘specified imaging service’ means an imaging service that is a Centers for Medicare & Medicaid Services-specified shoppable service (as described in subsection (a)(2)(A)(ii)(I)).”.
SEC. 104. AMBULATORY SURGICAL CENTER PRICE TRANSPARENCY.

Section 1834 of the Social Security Act (42 U.S.C. 1395m) is amended by adding at the end the following new subsection:

“(aa) AMBULATORY SURGICAL CENTER PRICE TRANSPARENCY.—

“(1) IN GENERAL.—Beginning January 1, 2026, each specified ambulatory surgical center that receives payment under this title for furnishing items and services shall comply with the price transparency requirement described in paragraph (2).

“(2) REQUIREMENT DESCRIBED.—

“(A) IN GENERAL.—For purposes of paragraph (1), the price transparency requirement described in this subsection is, with respect to a specified ambulatory surgical center, that such surgical center in accordance with a method and format established by the Secretary under subparagraph (C)), compile and make public (without subscription and free of charge), for each year—

“(i) all of the ambulatory surgical center’s standard charges (including the information described in subparagraph
(B)) for each item and service furnished by such surgical center;

“(ii) information on the ambulatory surgical center’s prices (including the information described in subparagraph (B)) for as many of the Centers for Medicare & Medicaid Services-specified shoppable services that are furnished by such surgical center, and as many additional ambulatory surgical center-selected shoppable services (or all such additional services, if such surgical center furnishes fewer than 300 shoppable services) as may be necessary for a combined total of at least 300 shoppable services; and

“(iii) with respect to each Centers for Medicare & Medicaid Services-specified shoppable service that is not furnished by the ambulatory surgical center, an indication that such service is not so furnished.

“(B) INFORMATION DESCRIBED.—For purposes of subparagraph (A), the information described in this subparagraph is, with respect to standard charges and prices (as applicable)
made public by a specified ambulatory surgical center, the following:

“(i) A plain language description of each item or service, accompanied by, as applicable, the Healthcare Common Procedure Coding System code, the diagnosis-related group, the national drug code, or other identifier used or approved by the Centers for Medicare & Medicaid Services.

“(ii) The gross charge, as applicable, expressed as a dollar amount, for each such item or service.

“(iii) The discounted cash price, as applicable, expressed as a dollar amount, for each such item or service (or, in the case no discounted cash price is available for an item or service, the median cash price charged to self-pay individuals for such item or service for the previous three years, expressed as a dollar amount).

“(iv) The current payer-specific negotiated charges, clearly associated with the name of the third party payer and plan and expressed as a dollar amount, that applies to each such item or service.
“(v) The de-identified maximum and minimum negotiated charges, as applicable, for each such item or service.

“(vi) Any other additional information the Secretary may require for the purpose of improving the accuracy of, or enabling consumers to easily understand and compare, standard charges and prices for an item or service, except information that is duplicative of any other reporting requirement under this subsection.

“(C) UNIFORM METHOD AND FORMAT.—Not later than January 1, 2026, the Secretary shall establish a standard, uniform method and format for specified ambulatory surgical centers to use in making public standard charges and a standard, uniform method and format for such centers to use in making public prices pursuant to subparagraph (A). Any such method and format—

“(i) shall, in the case of such charges made public by an ambulatory surgical center, ensure that such charges are made available in a machine-readable format (or successor technology);
“(ii) may be similar to any template made available by the Centers for Medicare & Medicaid Services as of the date of the enactment of this paragraph; “

“(iii) shall meet such standards as determined appropriate by the Secretary in order to ensure the accessibility and usability of such charges and prices; and 

“(iv) shall be updated as determined appropriate by the Secretary, in consultation with stakeholders. 

“(3) MONITORING COMPLIANCE.—The Secretary shall, through notice and comment rulemaking and in consultation with the Inspector General of the Department of Health and Human Services, establish a process to monitor compliance with this subsection. Such process shall ensure that each specified ambulatory surgical center’s compliance with this subsection is reviewed not less frequently than once every 3 years.

“(4) ENFORCEMENT.—

“(A) IN GENERAL.—In the case of a specified ambulatory surgical center that fails to comply with the requirements of this subsection—"
“(i) the Secretary shall notify such ambulatory surgical center of such failure not later than 30 days after the date on which the Secretary determines such failure exists; and

“(ii) upon request of the Secretary, the ambulatory surgical center shall submit to the Secretary, not later than 45 days after the date of such request, a corrective action plan to comply with such requirements.

“(B) CIVIL MONETARY PENALTY.—

“(i) IN GENERAL.—In addition to any other enforcement actions or penalties that may apply under another provision of law, a specified ambulatory surgical center that has received a notification under subparagraph (A)(i) and fails to comply with the requirements of this subsection by the date that is 90 days after such notification (or, in the case of an ambulatory surgical center that has submitted a corrective action plan described in subparagraph (A)(ii) in response to a request so described, by the date that is 90 days after such submission)
shall be subject to a civil monetary penalty of an amount specified by the Secretary for each subsequent day during which such failure is ongoing (not to exceed $300 per day).

“(ii) INCREASE AUTHORITY.—In applying this subparagraph with respect to violations occurring in 2027 or a subsequent year, the Secretary may through notice and comment rulemaking increase the limitation on the per day amount of any penalty applicable to a specified ambulatory surgical center under clause (i).

“(iii) APPLICATION OF CERTAIN PROVISIONS.—The provisions of section 1128A (other than subsections (a) and (b) of such section) shall apply to a civil monetary penalty imposed under this subparagraph in the same manner as such provisions apply to a civil monetary penalty imposed under subsection (a) of such section.

“(iv) AUTHORITY TO WAIVE OR REDUCE PENALTY.—

“(I) IN GENERAL.—Subject to subclause (II), the Secretary may
waive any penalty, or reduce any penalty by not more than 75 percent, otherwise applicable under this subparagraph with respect to a specified ambulatory surgical center located in a rural or underserved area if the Secretary certifies that imposition of such penalty would result in an immediate threat to access to care for individuals in the service area of such surgical center.

“(II) LIMITATION ON APPLICATION.—The Secretary may not elect to waive a penalty under subclause (I) with respect to a specified ambulatory surgical center more than once in a 6-year period and may not elect to reduce such a penalty with respect to such a surgical center more than once in such a period. Nothing in the preceding sentence shall be construed as prohibiting the Secretary from both waiving and reducing a penalty with respect to a specified surgical center during a 6-year period.
“(5) Definitions.—For purposes of this section:

“(A) Discounted cash price.—The term ‘discounted cash price’ means the charge that applies to an individual who pays cash, or cash equivalent, for an item or service furnished by an ambulatory surgical center.

“(B) Federal health care program.—The term ‘Federal health care program’ has the meaning given such term in section 1128B.

“(C) Gross charge.—The term ‘gross charge’ means the charge for an individual item or service that is reflected on a specified surgical center’s chargemaster, absent any discounts.

“(D) Group health plan; group health insurance coverage; individual health insurance coverage.—The terms ‘group health plan’, ‘group health insurance coverage’, and ‘individual health insurance coverage’ have the meaning given such terms in section 2791 of the Public Health Service Act.

“(E) Payer-specific negotiated charge.—The term ‘payer-specific negotiated charge’ means the charge that a specified sur-
gical center has negotiated with a third party payer for an item or service.

“(F) Shoppable service.—The term ‘shoppable service’ means a service that can be scheduled by a health care consumer in advance and includes all ancillary items and services customarily furnished as part of such service.

“(G) Specified ambulatory surgical center.—The term ‘specified ambulatory surgical center’ means an ambulatory surgical center with respect to which a hospital (or any person with an ownership or control interest (as defined in section 1124(a)(3)) in a hospital) is a person with an ownership or control interest (as so defined).

“(H) Third party payer.—The term ‘third party payer’ means an entity that is, by statute, contract, or agreement, legally responsible for payment of a claim for a health care item or service.”.

SEC. 105. HEALTH COVERAGE PRICE TRANSPARENCY.

(a) Price Transparency Requirements.—

(1) IRC.—
(A) IN GENERAL.—Section 9819 of the Internal Revenue Code of 1986 is amended to read as follows:

“SEC. 9819. TRANSPARENCY IN COVERAGE.

“(a) COST SHARING TRANSPARENCY.—

“(1) IN GENERAL.—For plan years beginning on or after January 1, 2026, a group health plan shall permit a participant or beneficiary to learn the amount of cost-sharing (including deductibles, co-payments, and coinsurance) under the participant or beneficiary’s plan that the participant or beneficiary would be responsible for paying with respect to the furnishing of a specific item or service by a provider in a timely manner upon the request of the participant or beneficiary. At a minimum, such information shall include the information specified in paragraph (2) and shall be made available to such participant or beneficiary through a self-service tool that meets the requirements of paragraph (3) or, at the option of such participant or beneficiary, through a paper disclosure or phone or other electronic disclosure (as selected by such participant or beneficiary and provided at no cost to such participant or beneficiary) that meets such requirements as the Secretary may specify.
“(2) SPECIFIED INFORMATION.—For purposes of paragraph (1), the information specified in this paragraph is, with respect to an item or service for which benefits are available under a group health plan furnished by a health care provider to a participant or beneficiary of such plan, the following:

“(A) If such provider is a participating provider with respect to such item or service, the in-network rate (as defined in subsection (c)) for such item or service.

“(B) If such provider is not a participating provider with respect to such item or service, the maximum allowed amount or other dollar amount that such plan or coverage will recognize as payment for such item or service, along with a notice that such participant or beneficiary may be liable for additional charges.

“(C) The estimated amount of cost sharing (including deductibles, copayments, and coinsurance) that the participant or beneficiary will incur for such item or service (which, in the case such item or service is to be furnished by a provider described in subparagraph (B), shall be calculated using the maximum allowed
amount or other dollar amount described in such subparagraph).

“(D) The amount the participant or beneficiary has already accumulated with respect to any deductible or out of pocket maximum under the plan (broken down, in the case separate deductibles or maximums apply to separate participants and beneficiaries enrolled in the plan, by such separate deductibles or maximums, in addition to any cumulative deductible or maximum).

“(E) In the case such plan imposes any frequency or volume limitations with respect to such item or service (excluding medical necessity determinations), the amount that such participant or beneficiary has accrued towards such limitation with respect to such item or service.

“(F) Any prior authorization, concurrent review, step therapy, fail first, or similar requirements applicable to coverage of such item or service under such plan.

“(G) Any shared savings (such as any credit, payment, or other benefit provided by such plan) available to the participant or beneficiary with respect to such item or service fur-
nished by such provider known at the time such
request is made.

“(3) SELF-SERVICE TOOL.—For purposes of
paragraph (1), a self-service tool established by a
group health plan meets the requirements of this
paragraph if such tool—

“(A) is based on an Internet website (or
successor technology specified by the Sec-
retary);

“(B) provides for real-time responses to re-
quests described in paragraph (1);

“(C) is updated in a manner such that in-
formation provided through such tool is timely
and accurate at the time such request is made;

“(D) allows such a request to be made
with respect to an item or service furnished
by—

“(i) a specific provider that is a par-
ticipating provider with respect to such
item or service;

“(ii) all providers that are partici-
pating providers with respect to such item
or service; or
“(iii) a provider in a relevant geographic region that is not described in clause (i) or (ii);

“(E) provides that such a request may be made with respect to an item or service through use of the billing code for such item or service or through use of a descriptive term for such item or service; and

“(F) meets any other requirement determined appropriate by the Secretary to ensure the accessibility and usability of information provided through such tool.

The Secretary may require such tool, as a condition of complying with subparagraph (E), to link multiple billing codes to a single descriptive term if the Secretary determines that the billing codes to be so linked correspond to similar items and services.

“(b) RATE AND PAYMENT INFORMATION.—

“(1) IN GENERAL.—For plan years beginning on or after January 1, 2026, each group health plan (other than a grandfathered health plan (as defined in section 1251(e) of the Patient Protection and Affordable Care Act)) shall, for each month, not later than the tenth day of such month, make available to the public the rate and payment information de-
scribed in paragraph (2) in accordance with para-
graph (3).

“(2) RATE AND PAYMENT INFORMATION DES-
CRIBED.—For purposes of paragraph (1), the rate
and payment information described in this para-
graph is, with respect to a group health plan, the
following:

“(A) With respect to each item or service
(other than a drug) for which benefits are avail-
able under such plan, the in-network rate (ex-
pressed as a dollar amount) in effect as of the
date on which such information is made public
with each provider that is a participating pro-
vider with respect to such item or service.

“(B) With respect to each drug (identified
by national drug code) for which benefits are
available under such plan—

“(i) the in-network rate (expressed as
a dollar amount) in effect as of the first
day of the month in which such informa-
tion is made public with each provider that
is a participating provider with respect to
such drug; and

“(ii) the average amount paid by such
plan (net of rebates, discounts, and price
concessions) for such drug dispensed or administered during the 90-day period beginning 180 days before such date of publication to each provider that was a participating provider with respect to such drug, broken down by each such provider, other than such an amount paid to a provider that, during such period, submitted fewer than 20 claims for such drug to such plan.

“(C) With respect to each item or service for which benefits are available under such plan, the amount billed, and the amount allowed by the plan, for each such item or service furnished during the 90-day period specified in subparagraph (B) by a provider that was not a participating provider with respect to such item or service, broken down by each such provider.

“(3) MANNER OF PUBLICATION.—Rate and payment information required to be made available under this subsection shall be so made available in dollar amounts through separate machine-readable files (and any successor technology, such as application program interface technology, determined appropriate by the Secretary) corresponding to the information described in each of subparagraphs (A)
through (C) of paragraph (2) that meet such re-
quirements as specified by the Secretary through
subregulatory guidance. Such requirements shall en-
sure that such files are limited to an appropriate
size, do not include disclosure of unnecessary dupli-
cative information contained in other files made
available under this subsection, are made available
in a widely-available format through a publicly-avail-
able website that allows for information contained in
such files to be compared across group health plans
and group or individual health insurance coverage,
and are accessible to individuals at no cost and with-
out the need to establish a user account or provide
other credentials.

“(4) USER INSTRUCTIONS.—Each group health
plan shall make available to the public instructions
written in plain language explaining how individuals
may search for information described in paragraph
(2) in files submitted in accordance with paragraph
(3). The Secretary shall develop and publish through
subregulatory guidance a template that such a plan
may use in developing instructions for purposes of
the preceding sentence.

“(5) SUMMARY.—For each plan year beginning
on or after January 1, 2026, each group health plan
shall make public a data file, in a manner that en-
sures that such file may be easily downloaded and
read by standard spreadsheet software and that
meets such requirements as established by the Sec-
retary, containing a summary of all rate and pay-
ment information made public by such plan with re-
spect to such plan during such plan year. Such file
shall include the following:

“(A) The mean, median, and interquartile
range of the in-network rate, and the amount
allowed for an item or service when not fur-
nished by a participating provider, in effect as
of the first day of such plan year for each item
or service (identified by payer identifier ap-
proved or used by the Centers for Medicare &
Medicaid Services) for which benefits are avail-
able under the plan, broken down by the type
of provider furnishing the item or service and
by the geographic area in which such item or
service is furnished.

“(B) Trends in payment rates for such
items and services over such plan year, includ-
ing an identification of instances in which such
rates have increased, decreased, or remained
the same.
“(C) The name of such plan, a description of the type of network of participating providers used by such plan, and a description of whether such plan is self-insured or fully-insured.

“(D) For each item or service which is paid as part of a bundled rate—

“(i) a description of the formulae, pricing methodologies, or other information used to calculate the payment rate for such bundle; and

“(ii) a list of the items and services included in such bundle.

“(E) The percentage of items and services that are paid for on a fee-for-service basis and the percentage of items and services that are paid for as part of a bundled rate, capitated payment rate, or other alternative payment model.

“(6) ATTESTATION.—Each group health plan shall post, along with rate and payment information made public by such plan, an attestation that such information is complete and accurate.

“(c) ACCESSIBILITY.—A group health plan shall take reasonable steps (as specified by the Secretary) to ensure that information provided in response to a request de-
scribed in subsection (a), and rate and payment information made public under subsection (b), is provided in plain, easily understandable language and that interpretation, translations, and assistive services are provided to those with limited English proficiency and those with disabilities.

“(d) DEFINITIONS.—In this section:

“(1) PARTICIPATING PROVIDER.—The term ‘participating provider’ means, with respect to an item or service and a group health plan, a physician or other health care provider who is acting within the scope of practice of that provider’s license or certification under applicable State law and who has a contractual relationship with the plan, respectively, for furnishing such item or service under the plan, and includes facilities, respectively.

“(2) PROVIDER.—The term ‘provider’ includes a health care facility.

“(3) IN-NETWORK RATE.—The term ‘in-network rate’ means, with respect to a group health plan and an item or service furnished by a provider that is a participating provider with respect to such plan and item or service, the contracted rate (reflected as a dollar amount) in effect between such plan and such provider for such item or service, re-
gardless of whether such rate is calculated based on a set amount, a fee schedule, or an amount derived from another amount, or a formula, or other method.”.

(B) CLERICAL AMENDMENT.—The item relating to section 9819 of the table of sections for subchapter B of chapter 100 of the Internal Revenue Code of 1986 is amended to read as follows:

“Sec. 9819. Transparency in coverage.”.

(2) PHSA.—Section 2799A–4 of the Public Health Service Act (42 U.S.C. 300gg–114) is amended to read as follows:

“SEC. 2799A–4. TRANSPARENCY IN COVERAGE.

“(a) COST SHARING TRANSPARENCY.—

“(1) IN GENERAL.—For plan years beginning on or after January 1, 2026, a group health plan and a health insurance issuer offering group or individual health insurance coverage shall permit an individual enrolled under such plan or coverage to learn the amount of cost-sharing (including deductibles, copayments, and coinsurance) under the individual’s plan or coverage that the individual would be responsible for paying with respect to the furnishing of a specific item or service by a provider in a timely manner upon the request of the indi-
vidual. At a minimum, such information shall include the information specified in paragraph (2) and shall be made available to such individual through a self-service tool that meets the requirements of paragraph (3) or, at the option of such individual, through a paper disclosure or phone or other electronic disclosure (as selected by such individual and provided at no cost to such individual) that meets such requirements as the Secretary may specify.

“(2) SPECIFIED INFORMATION.—For purposes of paragraph (1), the information specified in this paragraph is, with respect to an item or service for which benefits are available under a group health plan or group or individual health insurance coverage furnished by a health care provider to an individual enrolled under such plan or coverage, the following:

“(A) If such provider is a participating provider with respect to such item or service, the in-network rate (as defined in subsection (c)) for such item or service.

“(B) If such provider is not a participating provider with respect to such item or service, the maximum allowed amount or other dollar amount that such plan or coverage will recog-
nize as payment for such item or service, along
with a notice that such individual may be liable
for additional charges.

“(C) The estimated amount of cost sharing
(including deductibles, copayments, and coin-
surance) that the individual will incur for such
item or service (which, in the case such item or
service is to be furnished by a provider de-
scribed in subparagraph (B), shall be calculated
using the maximum allowed amount or other
dollar amount described in such subparagraph).

“(D) The amount the individual has al-
ready accumulated with respect to any deduct-
ible or out of pocket maximum under the plan
or coverage (broken down, in the case separate
deductibles or maximums apply to separate in-
dividuals enrolled in the plan or coverage, by
such separate deductibles or maximums, in ad-
dition to any cumulative deductible or max-
imum).

“(E) In the case such plan imposes any
frequency or volume limitations with respect to
such item or service (excluding medical neces-
sity determinations), the amount that such indi-
individual has accrued towards such limitation with
respect to such item or service.

“(F) Any prior authorization, concurrent
review, step therapy, fail first, or similar re-
quirements applicable to coverage of such item
or service under such plan or coverage.

“(G) Any shared savings (such as any
credit, payment, or other benefit provided by
such plan or issuer) available to the individual
with respect to such item or service furnished
by such provider known at the time such re-
quest is made.

“(3) SELF-SERVICE TOOL.—For purposes of
paragraph (1), a self-service tool established by a
group health plan or health insurance issuer offering
group or individual health insurance coverage meets
the requirements of this paragraph if such tool—

“(A) is based on an Internet website (or
successor technology specified by the Sec-
retary);

“(B) provides for real-time responses to re-
quests described in paragraph (1);

“(C) is updated in a manner such that in-
formation provided through such tool is timely
and accurate at the time such request is made;
“(D) allows such a request to be made with respect to an item or service furnished by—

“(i) a specific provider that is a participating provider with respect to such item or service;

“(ii) all providers that are participating providers with respect to such item or service; or

“(iii) a provider in a relevant geographic region that is not described in clause (i) or (ii);

“(E) provides that such a request may be made with respect to an item or service through use of the billing code for such item or service or through use of a descriptive term for such item or service; and

“(F) meets any other requirement determined appropriate by the Secretary to ensure the accessibility and usability of information provided through such tool.

The Secretary may require such tool, as a condition of complying with subparagraph (E), to link multiple billing codes to a single descriptive term if the Sec-
retary determines that the billing codes to be so
linked correspond to similar items and services.

“(b) RATE AND PAYMENT INFORMATION.—

“(1) IN GENERAL.—For plan years beginning
on or after January 1, 2026, each group health plan
and health insurance issuer offering group or indi-
vidual health insurance coverage (other than a
grandfathered health plan (as defined in section
1251(e) of the Patient Protection and Affordable
Care Act)) shall, for each month, not later than the
tenth day of such month, make available to the pub-
lic the rate and payment information described in
paragraph (2) in accordance with paragraph (3).

“(2) RATE AND PAYMENT INFORMATION DE-
scribed.—For purposes of paragraph (1), the rate
and payment information described in this para-
graph is, with respect to a group health plan or
group or individual health insurance coverage, the
following:

“(A) With respect to each item or service
(other than a drug) for which benefits are avail-
able under such plan or coverage, the in-net-
work rate (expressed as a dollar amount) in ef-
fect as of the date on which such information
is made public with each provider that is a par-
ticipating provider with respect to such item or service.

“(B) With respect to each drug (identified by national drug code) for which benefits are available under such plan or coverage—

“(i) the in-network rate (expressed as a dollar amount) in effect as of the first day of the month in which such information is made public with each provider that is a participating provider with respect to such drug; and

“(ii) the average amount paid by such plan (net of rebates, discounts, and price concessions) for such drug dispensed or administered during the 90-day period beginning 180 days before such date of publication to each provider that was a participating provider with respect to such drug, broken down by each such provider, other than such an amount paid to a provider that, during such period, submitted fewer than 20 claims for such drug to such plan or coverage.

“(C) With respect to each item or service for which benefits are available under such plan
or coverage, the amount billed, and the amount
allowed by the plan, for each such item or serv-
vice furnished during the 90-day period specified
in subparagraph (B) by a provider that was not
a participating provider with respect to such
item or service, broken down by each such pro-
vider.

“(3) MANNER OF PUBLICATION.—Rate and
payment information required to be made available
under this subsection shall be so made available in
dollar amounts through separate machine-readable
files (and any successor technology, such as applica-
tion program interface technology, determined ap-
propriate by the Secretary) corresponding to the in-
formation described in each of subparagraphs (A)
through (C) of paragraph (2) that meet such re-
quirements as specified by the Secretary through
subregulatory guidance. Such requirements shall en-
sure that such files are limited to an appropriate
size, do not include disclosure of unnecessary duplic-
cative information contained in other files made
available under this subsection, are made available
in a widely-available format through a publicly-avail-
able website that allows for information contained in
such files to be compared across group health plans
and group or individual health insurance coverage, and are accessible to individuals at no cost and without the need to establish a user account or provide other credentials.

“(4) USER INSTRUCTIONS.—Each group health plan and health insurance issuer offering group or individual health insurance coverage shall make available to the public instructions written in plain language explaining how individuals may search for information described in paragraph (2) in files submitted in accordance with paragraph (3). The Secretary shall develop and publish through subregulatory guidance a template that such a plan may use in developing instructions for purposes of the preceding sentence.

“(5) SUMMARY.—For each plan year beginning on or after January 1, 2026, each group health plan and health insurance issuer offering group or individual health insurance coverage shall make public a data file, in a manner that ensures that such file may be easily downloaded and read by standard spreadsheet software and that meets such requirements as established by the Secretary, containing a summary of all rate and payment information made public by such plan or issuer with respect to such
plan or coverage during such plan year. Such file shall include the following:

“(A) The mean, median, and interquartile range of the in-network rate, and the amount allowed for an item or service when not furnished by a participating provider, in effect as of the first day of such plan year for each item or service (identified by payer identifier approved or used by the Centers for Medicare & Medicaid Services) for which benefits are available under the plan or coverage, broken down by the type of provider furnishing the item or service and by the geographic area in which such item or service is furnished.

“(B) Trends in payment rates for such items and services over such plan year, including an identification of instances in which such rates have increased, decreased, or remained the same.

“(C) The name of such plan, a description of the type of network of participating providers used by such plan or coverage, and, in the case of a group health plan, a description of whether such plan is self-insured or fully-insured.
“(D) For each item or service which is paid as part of a bundled rate—

“(i) a description of the formulae, pricing methodologies, or other information used to calculate the payment rate for such bundle; and

“(ii) a list of the items and services included in such bundle.

“(E) The percentage of items and services that are paid for on a fee-for-service basis and the percentage of items and services that are paid for as part of a bundled rate, capitated payment rate, or other alternative payment model.

“(6) ATTESTATION.—Each group health plan and health insurance issuer offering group or individual health insurance coverage shall post, along with rate and payment information made public by such plan or issuer, an attestation that such information is complete and accurate.

“(c) ACCESSIBILITY.—A group health plan and a health insurance issuer offering group or individual health insurance coverage shall take reasonable steps (as specified by the Secretary) to ensure that information provided in response to a request described in subsection (a), and
rate and payment information made public under subsection (b), is provided in plain, easily understandable language and that interpretation, translations, and assistive services are provided to those with limited English proficiency and those with disabilities.

“(d) DEFINITIONS.—In this section:

“(1) PARTICIPATING PROVIDER.—The term ‘participating provider’ means, with respect to an item or service and a group health plan or health insurance issuer offering group or individual health insurance coverage, a physician or other health care provider who is acting within the scope of practice of that provider’s license or certification under applicable State law and who has a contractual relationship with the plan or issuer, respectively, for furnishing such item or service under the plan or coverage, and includes facilities, respectively.

“(2) PROVIDER.—The term ‘provider’ includes a health care facility.

“(3) IN-NETWORK RATE.—The term ‘in-network rate’ means, with respect to a group health plan or group or individual health insurance coverage and an item or service furnished by a provider that is a participating provider with respect to such plan or coverage and item or service, the contracted
rate (reflected as a dollar amount) in effect between
such plan or coverage and such provider for such
item or service, regardless of whether such rate is
calculated based on a set amount, a fee schedule, or
an amount derived from another amount, or a for-
mula, or other method.”

(3) ERISA.—

(A) IN GENERAL.—Section 719 of the Em-
ployee Retirement Income Security Act of 1974
(29 U.S.C. 1185h) is amended to read as fol-

“SEC. 719. TRANSPARENCY IN COVERAGE.

“(a) COST SHARING TRANSPARENCY.—

“(1) IN GENERAL.—For plan years beginning
on or after January 1, 2026, a group health plan
and a health insurance issuer offering group health
insurance coverage shall permit a participant or ben-
eficiary to learn the amount of cost-sharing (includ-
ing deductibles, copayments, and coinsurance) under
the participant or beneficiary’s plan or coverage that
the participant or beneficiary would be responsible
for paying with respect to the furnishing of a spe-
cific item or service by a provider in a timely man-
ner upon the request of the participant or bene-
ficiary. At a minimum, such information shall in-
clude the information specified in paragraph (2) and shall be made available to such participant or beneficiary through a self-service tool that meets the requirements of paragraph (3) or, at the option of such participant or beneficiary, through a paper disclosure or phone or other electronic disclosure (as selected by such participant or beneficiary and provided at no cost to such participant or beneficiary) that meets such requirements as the Secretary may specify.

“(2) SPECIFIED INFORMATION.—For purposes of paragraph (1), the information specified in this paragraph is, with respect to an item or service for which benefits are available under a group health plan or group health insurance coverage furnished by a health care provider to a participant or beneficiary of such plan or coverage, the following:

“(A) If such provider is a participating provider with respect to such item or service, the in-network rate (as defined in subsection (c)) for such item or service.

“(B) If such provider is not a participating provider with respect to such item or service, the maximum allowed amount or other dollar amount that such plan or coverage will recog-
nize as payment for such item or service, along with a notice that such participant or beneficiary may be liable for additional charges.

“(C) The estimated amount of cost sharing (including deductibles, copayments, and coinsurance) that the participant or beneficiary will incur for such item or service (which, in the case such item or service is to be furnished by a provider described in subparagraph (B), shall be calculated using the maximum allowed amount or other dollar amount described in such subparagraph).

“(D) The amount the participant or beneficiary has already accumulated with respect to any deductible or out of pocket maximum under the plan or coverage (broken down, in the case separate deductibles or maximums apply to separate participants and beneficiaries enrolled in the plan or coverage, by such separate deductibles or maximums, in addition to any cumulative deductible or maximum).

“(E) In the case such plan imposes any frequency or volume limitations with respect to such item or service (excluding medical necessity determinations), the amount that such par-
participant or beneficiary has accrued towards such
limitation with respect to such item or service.

“(F) Any prior authorization, concurrent
review, step therapy, fail first, or similar re-
quirements applicable to coverage of such item
or service under such plan or coverage.

“(G) Any shared savings (such as any
credit, payment, or other benefit provided by
such plan or issuer) available to the participant
or beneficiary with respect to such item or serv-
ice furnished by such provider known at the
time such request is made.

“(3) SELF-SERVICE TOOL.—For purposes of
paragraph (1), a self-service tool established by a
group health plan or health insurance issuer offering
group health insurance coverage meets the require-
ments of this paragraph if such tool—

“(A) is based on an Internet website (or
successor technology specified by the Sec-
retary);”

“(B) provides for real-time responses to re-
quests described in paragraph (1);”

“(C) is updated in a manner such that in-
formation provided through such tool is timely
and accurate at the time such request is made;
“(D) allows such a request to be made with respect to an item or service furnished by—

“(i) a specific provider that is a participating provider with respect to such item or service;

“(ii) all providers that are participating providers with respect to such item or service; or

“(iii) a provider in a relevant geographic region that is not described in clause (i) or (ii);

“(E) provides that such a request may be made with respect to an item or service through use of the billing code for such item or service or through use of a descriptive term for such item or service; and

“(F) meets any other requirement determined appropriate by the Secretary to ensure the accessibility and usability of information provided through such tool.

The Secretary may require such tool, as a condition of complying with subparagraph (E), to link multiple billing codes to a single descriptive term if the Sec-
retary determines that the billing codes to be so
linked correspond to similar items and services.

“(b) Rate and Payment Information.—

“(1) In general.—For plan years beginning
on or after January 1, 2026, each group health plan
and health insurance issuer offering group health in-
surance coverage (other than a grandfathered health
plan (as defined in section 1251(e) of the Patient
Protection and Affordable Care Act)) shall, for each
month, not later than the tenth day of such month,
make available to the public the rate and payment
information described in paragraph (2) in accord-
ance with paragraph (3).

“(2) Rate and payment information de-
scribed.—For purposes of paragraph (1), the rate
and payment information described in this para-
graph is, with respect to a group health plan or
group health insurance coverage, the following:

“(A) With respect to each item or service
(other than a drug) for which benefits are avail-
able under such plan or coverage, the in-net-
work rate (expressed as a dollar amount) in ef-
fect as of the date on which such information
is made public with each provider that is a par-
participating provider with respect to such item or service.

“(B) With respect to each drug (identified by national drug code) for which benefits are available under such plan or coverage—

“(i) the in-network rate (expressed as a dollar amount) in effect as of the first day of the month in which such information is made public with each provider that is a participating provider with respect to such drug; and

“(ii) the average amount paid by such plan (net of rebates, discounts, and price concessions) for such drug dispensed or administered during the 90-day period beginning 180 days before such date of publication to each provider that was a participating provider with respect to such drug, broken down by each such provider, other than such an amount paid to a provider that, during such period, submitted fewer than 20 claims for such drug to such plan or coverage.

“(C) With respect to each item or service for which benefits are available under such plan
or coverage, the amount billed, and the amount
allowed by the plan, for each such item or serv-
ice furnished during the 90-day period specified
in subparagraph (B) by a provider that was not
a participating provider with respect to such
item or service, broken down by each such pro-
vider.

“(3) MANNER OF PUBLICATION.—Rate and
payment information required to be made available
under this subsection shall be so made available in
dollar amounts through separate machine-readable
files (and any successor technology, such as applica-
tion program interface technology, determined ap-
propriate by the Secretary) corresponding to the in-
formation described in each of subparagraphs (A)
through (C) of paragraph (2) that meet such re-
quirements as specified by the Secretary through
subregulatory guidance. Such requirements shall en-
sure that such files are limited to an appropriate
size, do not include disclosure of unnecessary dupli-
cative information contained in other files made
available under this subsection, are made available
in a widely-available format through a publicly-avail-
able website that allows for information contained in
such files to be compared across group health plans
and group or individual health insurance coverage, and are accessible to individuals at no cost and without the need to establish a user account or provide other credentials.

“(4) USER INSTRUCTIONS.—Each group health plan and health insurance issuer offering group health insurance coverage shall make available to the public instructions written in plain language explaining how individuals may search for information described in paragraph (2) in files submitted in accordance with paragraph (3). The Secretary shall develop and publish through subregulatory guidance a template that such a plan may use in developing instructions for purposes of the preceding sentence.

“(5) SUMMARY.—For each plan year beginning on or after January 1, 2026, each group health plan and health insurance issuer offering group health insurance coverage shall make public a data file, in a manner that ensures that such file may be easily downloaded and read by standard spreadsheet software and that meets such requirements as established by the Secretary, containing a summary of all rate and payment information made public by such plan or issuer with respect to such plan or coverage
during such plan year. Such file shall include the fol-
lowing:

“(A) The mean, median, and interquartile
range of the in-network rate, and the amount
allowed for an item or service when not fur-
nished by a participating provider, in effect as
of the first day of such plan year for each item
or service (identified by payer identifier ap-
proved or used by the Centers for Medicare &
Medicaid Services) for which benefits are avail-
able under the plan or coverage, broken down
by the type of provider furnishing the item or
service and by the geographic area in which
such item or service is furnished.

“(B) Trends in payment rates for such
items and services over such plan year, includ-
ing an identification of instances in which such
rates have increased, decreased, or remained
the same.

“(C) The name of such plan, a description
of the type of network of participating providers
used by such plan or coverage, and, in the case
of a group health plan, a description of whether
such plan is self-insured or fully-insured.
“(D) For each item or service which is paid as part of a bundled rate—

“(i) a description of the formulae, pricing methodologies, or other information used to calculate the payment rate for such bundle; and

“(ii) a list of the items and services included in such bundle.

“(E) The percentage of items and services that are paid for on a fee-for-service basis and the percentage of items and services that are paid for as part of a bundled rate, capitated payment rate, or other alternative payment model.

“(6) ATTESTATION.—Each group health plan and health insurance issuer offering group health insurance coverage shall post, along with rate and payment information made public by such plan or issuer, an attestation that such information is complete and accurate.

“(c) ACCESSIBILITY.—A group health plan and a health insurance issuer offering group health insurance coverage shall take reasonable steps (as specified by the Secretary) to ensure that information provided in response to a request described in subsection (a), and rate and pay-
ment information made public under subsection (b), is
provided in plain, easily understandable language and that
interpretation, translations, and assistive services are pro-
vided to those with limited English proficiency and those
with disabilities.

“(d) DEFINITIONS.—In this section:

“(1) PARTICIPATING PROVIDER.—The term
‘participating provider’ means, with respect to an
item or service and a group health plan or health in-

urance issuer offering group or individual health in-

surance coverage, a physician or other health care

provider who is acting within the scope of practice

of that provider’s license or certification under appli-
cable State law and who has a contractual relation-

ship with the plan or issuer, respectively, for fur-

nishing such item or service under the plan or cov-

erage, and includes facilities, respectively.

“(2) PROVIDER.—The term ‘provider’ includes

a health care facility.

“(3) IN-NETWORK RATE.—The term ‘in-net-

work rate’ means, with respect to a group health

plan or group health insurance coverage and an item

or service furnished by a provider that is a partici-
pating provider with respect to such plan or cov-

erage and item or service, the contracted rate (re-
flected as a dollar amount) in effect between such plan or coverage and such provider for such item or service, regardless of whether such rate is calculated based on a set amount, a fee schedule, or an amount derived from another amount, or a formula, or other method.”.

(B) CLERICAL AMENDMENT.—The table of contents in section 1 of the Employee Retirement Income Security Act of 1974 is amended by striking the item relating to section 719 and inserting the following new item:

“Sec. 719. Transparency in coverage.”.

(b) APPLICATION PROGRAMMING INTERFACE REPORT.—Not later than January 1, 2025, the Secretary of Health and Human Services shall, in consultation with the Office of the National Coordinator for Health Information Technology, Department of Labor, the Department of the Treasury, and stakeholders, submit to the House Committees on Education and the Workforce, Energy and Commerce, and Ways and Means, and the Senate Committees on Finance and Health, Education, Labor, and Pensions a report on the use of standards-based application programming interfaces (in this subsection referred to as “APIs”) to facilitate access to health care price transparency information and the interoperability of other medical information. Such report shall include an evaluation
of the capacity of the Department of Health and Human Services, the Department of Labor, and the Department of the Treasury to regulate and implement standards related to APIs and recommendations for improving such capacity. Such report shall include the following:

(1) A description of current use, and proposed use, of APIs under Federal rules to facilitate interoperability, including information related to capacity constraints within the agencies, barriers to adoption, privacy and security, administrative burdens and efficiencies, care coordination, and levels of compliance.

(2) A description of the feasibility of agency participation in the development of APIs to enable application access to price transparency data under the amendments made by subsection (a).

(3) A specification of the timeline for which such data standards can be required to make such data accessible via an API.

(4) An analysis of the benefits and challenges of implementing standards-based APIs for price transparency data, including the ability for consumers to access rate and payment information and the amount of cost-sharing (including deductibles, copayments, and coinsurance) under the consumer’s
plan through third-party internet-based tools and applications.

(5) An analysis of the impact that APIs which provide real-time access to pricing and cost-sharing information may have in increasing the amount of services shoppable for individuals, such as by standardizing more health care spend via episode bundles.

(6) An analysis of which health care items and services may be useful under API, such as those for which prices change with the greatest frequency.

(7) An analysis of the cost of API standards implementation on issuers, employers, and other private-sector entities.

(8) An analysis of the ability of State regulators to enforce API standards and the costs to the Federal Government and States to regulate and enforce API standards.

(9) An analysis of the interaction with API standards and Federal health information privacy standards.

(c) PROVIDER TOOL REPORT.—

(1) IN GENERAL.—Not later than 1 year after the date of the enactment of this Act, The Secretary of Health and Human Services, acting through the Administrator of the Centers for Medicare & Med-
icaid Services, shall, in consultation with stakeholders, conduct a study and submit to the House Committees on Education and the Workforce, Energy and Commerce, and Ways and Means, and the Senate Committees on Finance and Health, Education, Labor, and Pensions a report on the usefulness and feasibility of the establishment of a provider tool by a group health plan, or a health insurance issuer offering group and individual health insurance coverage, in facilitating the provision of information made available pursuant to the amendments made by subsection (a). Such report shall include the following:

(A) A description of the feasibility of establishing a requirement for the various types of plans and coverage to offer such a provider tool, including any challenges to establishing a provider tool using the same technology platform as the self-service tool described in such amendments.

(B) An evaluation on the usefulness of a provider tool to aid patient-decision making and how such tool would coordinate with other information available to a patient and their pro-
vider under other Federal requirements in place or under consideration.

(C) An evaluation of whether the information provided by such tool would be duplicative of the advanced explanation of benefits required under Federal law or any other existing requirement.

(D) A description of the usability and expected utilization of such tool among providers, including among different provider types.

(E) An analysis of the impact of a provider tool in value-based care arrangements.

(F) An analysis on the potential impact of the provider tool on—

(i) patients' out-of-pocket spending;

(ii) plan design, including impacts on cost-sharing requirements;

(iii) care coordination and quality;

(iv) plan premiums;

(v) overall health care spending and utilization; and

(vi) health care access in rural areas.

(G) An analysis of the feasibility of a provider tool to include additional functionality to facilitate and improve the administration of the
requirements on providers to submit notifications to such plan or coverage under section 2799B–6 of the Public Health Service Act and the requirements on such plan or coverage to provide an advanced explanation of benefits to individuals under section 2799A–1(f) of such Act.

(H) An analysis of which health care items and services, would be most useful for patients utilizing a provider tool.

(I) An analysis of rulemaking required to ensure such a tool complies with federal health information privacy standards.

(J) An analysis of the burden and cost of the creation of a provider tool by plans and coverage on providers, issuers, employers, and other private-sector entities.

(K) An analysis of the ability of state regulators to enforce provider tool standards and the costs to the Department and states to regulate and enforce provider tool standards.

(2) DEFINITION.—The term “provider tool” means a tool designed to facilitate the provision of information made available pursuant to the amendments made by subsection (a) and established by a
group health plan or a health insurance issuer offering group and individual health insurance coverage that allows providers to access the information such plan or coverage must provide through the self-service tool described in such amendments to an individual with whom the provider is actively treating at the time of such request, upon the request of the provider, and with the consent of such individual.

(d) REPORTS.—

(1) COMPLIANCE.—Not later than January 1, 2027, the Comptroller General of the United States shall submit to Congress a report containing—

(A) an analysis of compliance with the amendments made by this section;

(B) an analysis of enforcement of such amendments by the Secretaries of Health and Human Services, Labor, and the Treasury;

(C) recommendations relating to improving such enforcement; and

(D) recommendations relating to improving public disclosure, and public awareness, of information required to be made available by group health plans and health insurance issuers pursuant to such amendments.
(2) PRICES.—Not later than January 1, 2028, and biennially thereafter, the Secretaries of Health and Human Services, Labor, and the Treasury shall jointly submit to Congress a report containing an assessment of differences in negotiated prices (and any trends in such prices) in the private market between—

(A) rural and urban areas;

(B) the individual, small group, and large group markets;

(C) consolidated and nonconsolidated health care provider areas (as specified by the Secretary of Health and Human Services);

(D) nonprofit and for-profit hospitals;

(E) nonprofit and for-profit insurers; and

(F) insurers serving local or regional areas and insurers serving multistate or national areas.

(e) QUALITY REPORT.—Not later than 1 year after the date of enactment of this subsection, the Secretaries of Health and Human Services, Labor, and the Treasury shall jointly submit to Congress a report on the feasibility of including data relating to the quality of health care items and services with the price transparency information required to be made available under the amendments.
made by subsection (a). Such report shall include recommendations for legislative and regulatory actions to identify appropriate metrics for assessing and comparing quality of care.

(f) CONTINUED APPLICABILITY OF RULES FOR PREVIOUS YEARS.—Nothing in the amendments made by subsection (a) may be construed as affecting the applicability of the rule entitled “Transparency in Coverage” published by the Department of the Treasury, the Department of Labor, and the Department of Health and Human Services on November 12, 2020 (85 Fed. Reg. 72158) for any plan year beginning before January 1, 2026.

SEC. 106. PHARMACY BENEFITS PRICE TRANSPARENCY.

(a) PHSA.—Title XXVII of the Public Health Service Act (42 U.S.C. 300gg et seq.) is amended—

(1) in part D (42 U.S.C. 300gg–111 et seq.), by adding at the end the following new section:

“SEC. 2799A–11. OVERSIGHT OF PHARMACY BENEFITS MANAGER SERVICES.

“(a) IN GENERAL.—For plan years beginning on or after the date that is 2 years after the date of enactment of this section, a group health plan or a health insurance issuer offering group health insurance coverage, or an entity or subsidiary providing pharmacy benefits management services on behalf of such a plan or issuer, shall not
enter into a contract with a drug manufacturer, distributor, wholesaler, subcontractor, rebate aggregator, or any other third party that limits (or delays beyond the applicable reporting period described in subsection (b)(1)) the disclosure of information to plan sponsors in such a manner that prevents such plan, issuer, or entity from making the reports described in subsection (b).

“(b) Reports.—

“(1) In general.—With respect to plan years beginning on or after the date that is 2 years after the date of enactment of this section, not less frequently than every 6 months (or at the request of a plan sponsor, not less frequently than quarterly, but under the same conditions, terms, and cost of the semiannual report under this subsection), a group health plan or health insurance issuer offering group health insurance coverage, or an entity providing pharmacy benefits management services on behalf of such a plan or issuer, shall submit to the plan sponsor (as defined in section 3(16)(B) of the Employee Retirement Income Security Act of 1974) of such plan or coverage a report in accordance with this section. Each such report shall be made available to such plan sponsor in a machine-readable for-
mat and shall include the information described in paragraph (2).

“(2) INFORMATION DESCRIBED.—For purposes of paragraph (1), the information described in this paragraph is, with respect to drugs covered by a group health plan or health insurance issuer offering group health insurance coverage during each reporting period—

“(A) a list of drugs for which a claim was filed and, with respect to each such drug on such list—

“(i) the brand name, chemical entity, and National Drug Code;

“(ii) the type of dispensing channel used to furnish such drug, including retail, mail order, or specialty pharmacy;

“(iii) with respect to each drug dispensed under each type of dispensing channel (including retail, mail order, or specialty pharmacy)—

“(I) whether such drug is a brand name drug or a generic drug, and—

“(aa) in the case of a brand name drug, the wholesale acquisi-
tion cost, listed as cost per days
supply and cost per dosage unit,
on the date such drug was dis-
pensed; and

“(bb) in the case of a ge-
neric drug, the average wholesale
price, listed as cost per days sup-
ply and cost per dosage unit, on
the date such drug was dis-
pensed; and

“(II) the total number of—

“(aa) prescription claims
(including original prescriptions
and refills);

“(bb) participants, bene-
ficiaries, and enrollees for whom
a claim for such drug was filed;

“(cc) dosage units per fill of
such drug; and

“(dd) days supply of such
drug per fill;

“(iv) the net price per course of treat-
ment or single fill, such as a 30-day supply
or 90-day supply to the plan or coverage
after manufacturer rebates, fees, and other remuneration or adjustments;

“(v) the total amount of out-of-pocket spending by participants, beneficiaries, and enrollees on such drug, including spending through copayments, coinsurance, and deductibles;

“(vi) the total net spending by the plan or coverage;

“(vii) total amount received, or expected to be received, by the plan or coverage from any entity in drug manufacturer rebates, fees, alternative discounts, and all other remuneration received from an entity or any third party (including group purchasing organizations) other than the plan sponsor;

“(viii) the total amount received, or expected to be received by the plan or issuer, from drug manufacturers in rebates, fees, alternative discounts, or other remuneration—

“(I) that has been paid, or is to be paid, by drug manufacturers for
claims incurred during the reporting period; and

“(II) that is related to utilization rebates for such drug; and

“(ix) to the extent feasible, information on the total amount of remuneration, including copayment assistance dollars paid, copayment cards applied, or other discounts provided by each drug manufacturer (or entity administering copay assistance on behalf of such drug manufacturer) to the participants, beneficiaries, and enrollees enrolled in such plan or coverage;

“(B) for each category or class of drugs for which a claim was filed, a breakdown of the total gross spending on drugs in such category or class before rebates, price concessions, alternative discounts, or other remuneration from drug manufacturers, and the net spending after such rebates, price concessions, alternative discounts, or other remuneration from drug manufacturers, including—

“(i) the number of participants, beneficiaries, and enrollees who filled a prescription for a drug in such category or
class, including the National Drug Code
for each such drug;

“(ii) if applicable, a description of the
formulary tiers and utilization mechanisms
(such as prior authorization or step ther-
apy) employed for drugs in that category
or class; and

“(iii) the total out-of-pocket spending
under the plan or coverage by participants,
bringees, and enrollees, including
spending through copayments, coinsurance,
and deductibles;

“(C) in the case of a drug for which gross
spending by such plan, coverage, or entity ex-
cceeded $10,000 during the reporting period—

“(i) a list of all other drugs in the
same therapeutic category or class; and

“(ii) the rationale for the formulary
placement of such drug in that therapeutic
category or class, if applicable;

“(D) amounts paid directly or indirectly in
rebates, fees, or any other type of compensation
(as defined in section 408(b)(2)(B)(ii)(dd)(AA)
of the Employee Retirement Income Security
Act) to brokers, consultants, advisors, or any
other individual or firm, for the referral of the

group health plan’s or health insurance issuer’s

business to an entity providing pharmacy bene-

fits management services, including the identity

of the recipient of such amounts;

“(E) an explanation of any benefit design

parameters that encourage or require partici-

pants, beneficiaries, and enrollees in such plan

or coverage to fill prescriptions at mail order,

specialty, or retail pharmacies that are affili-

ated with or under common ownership with the

entity providing pharmacy benefit management

services under such plan or coverage, including

mandatory mail and specialty home delivery

programs, retail and mail auto-refill programs,

and cost-sharing assistance incentives directly

or indirectly funded by such entity; and

“(F) in the case of a plan or coverage (or

an entity providing pharmacy benefits manage-

ment services on behalf of such plan or cov-

erage) that has an affiliated pharmacy or phar-

macy under common ownership—

“(i) the percentage of total prescrip-

tions dispensed by such pharmacies to in-

dividuals enrolled in such plan or coverage;
“(ii) a list of all drugs dispensed by such pharmacies to individuals enrolled in such plan or coverage, and, with respect to each drug dispensed—

“(I) the amount charged, per dosage unit, per 30-day supply, or per 90-day supply (as applicable) to the plan or issuer, and to participants, beneficiaries, and enrollees enrolled in such plan or coverage;

“(II) the median amount charged to such plan or issuer, and the inter-quartile range of the costs, per dosage unit, per 30-day supply, and per 90-day supply, including amounts paid by the participants, beneficiaries, and enrollees, when the same drug is dispensed by other pharmacies that are not affiliated with or under common ownership with the entity and that are included in the pharmacy network of such plan or coverage;

“(III) the lowest cost per dosage unit, per 30-day supply and per 90-day supply, for each such drug, in-
cluding amounts charged to the plan and participants, beneficiaries, and enrollees, that is available from any pharmacy included in the network of such plan or coverage; and

“(IV) the net acquisition cost per dosage unit, per 30-day supply, and per 90-day supply, if such drug is subject to a maximum price discount.

“(3) PRIVACY REQUIREMENTS.—Health insurance issuers offering group health insurance coverage and entities providing pharmacy benefits management services on behalf of a group health plan shall provide information under paragraph (1) in a manner consistent with the privacy, security, and breach notification regulations promulgated under section 13402(a) of the Health Information Technology for Clinical Health Act, and shall restrict the use and disclosure of such information according to such privacy regulations.

“(4) DISCLOSURE AND REDISCLOSURE.—

“(A) LIMITATION TO BUSINESS ASSOCIATES.—A plan sponsor receiving a report under paragraph (1) may disclose such information only to the entity from which the report was re-
ceived, the group health plan for which the report pertains, or to that entity’s business associates as defined in section 160.103 of title 45, Code of Federal Regulations (or successor regulations) or as permitted by the HIPAA Privacy Rule (45 CFR parts 160 and 164, subparts A and E).

“(B) CLARIFICATION REGARDING PUBLIC DISCLOSURE OF INFORMATION.—Nothing in this section shall prevent a group health plan or health insurance issuer offering group health insurance coverage, or an entity providing pharmacy benefits management services on behalf of such a plan or coverage, from placing reasonable restrictions on the public disclosure of the information contained in a report described in paragraph (1), except that such plan, issuer, or entity may not restrict disclosure of such report to the Department of Health and Human Services, the Department of Labor, the Department of the Treasury, or the Comptroller General of the United States.

“(C) LIMITED FORM OF REPORT.—The Secretary shall define through rulemaking a limited form of the report under paragraph (1)
required of plan sponsors who are drug manufacturers, drug wholesalers, or other direct participants in the drug supply chain, in order to prevent anti-competitive behavior.

“(5) REPORT TO GAO.—A group health plan or health insurance issuer offering group health insurance coverage, or an entity providing pharmacy benefits management services on behalf of such plan or coverage, shall submit to the Comptroller General of the United States each of the first 4 reports submitted to a plan sponsor under paragraph (1) and other such reports as requested, in accordance with the privacy requirements under paragraph (3), the disclosure and redisclosure standards under paragraph (4), the standards specified pursuant to paragraph (6), and such other information that the Comptroller General determines necessary to carry out the study under section 106(d) of the Lower Costs, More Transparency Act.

“(6) STANDARD FORMAT.—Not later than 1 year after the date of enactment of this section, the Secretary shall specify through rulemaking standards for group health plans, health insurance issuers offering group health insurance coverage, and entities providing pharmacy benefits management serv-
ices on behalf of such plans or coverage, required to submit reports under paragraph (1) to submit such reports in a standard format.

“(c) ENFORCEMENT.—

“(1) IN GENERAL.—The Secretary shall enforce this section.

“(2) FAILURE TO PROVIDE TIMELY INFORMATION.—A health insurance issuer or an entity providing pharmacy benefits management services on behalf of such plan or coverage that violates subsection (a) or fails to provide the information required under subsection (b) shall be subject to a civil monetary penalty in the amount of $10,000 for each day during which such violation continues or such information is not disclosed or reported.

“(3) FALSE INFORMATION.—A health insurance issuer or an entity providing pharmacy benefits management services on behalf of such a plan or coverage that knowingly provides false information under this section shall be subject to a civil money penalty in an amount not to exceed $100,000 for each item of false information. Such civil money penalty shall be in addition to other penalties as may be prescribed by law.
“(4) PROCEDURE.—The provisions of section 1128A of the Social Security Act, other than subsections (a) and (b) and the first sentence of subsection (c)(1) of such section shall apply to civil monetary penalties under this subsection in the same manner as such provisions apply to a penalty or proceeding under such section.

“(5) WAIVERS.—The Secretary may waive penalties under paragraph (2), or extend the period of time for compliance with a requirement of this section, for an entity in violation of this section that has made a good-faith effort to comply with the requirements in this section.

“(d) RULE OF CONSTRUCTION.—Nothing in this section shall be construed to permit a group health plan, health insurance issuer, or entity providing pharmacy benefits management services on behalf of such plan or coverage, to restrict disclosure to, or otherwise limit the access of, the Department of Health and Human Services to a report described in subsection (b)(1) or information related to compliance with subsections (a) or (b) by entities subject to such subsection.

“(e) DEFINITION.—In this section, the term ‘whole-sale acquisition cost’ has the meaning given such term in section 1847A(c)(6)(B) of the Social Security Act.”; and
(2) in section 2723 (42 U.S.C. 300gg–22)—

(A) in subsection (a)—

(i) in paragraph (1), by inserting

“(other than subsections (a) and (b) of section 2799A–11)” after “part D”; and

(ii) in paragraph (2), by inserting

“(other than subsections (a) and (b) of section 2799A–11)” after “part D”; and

(B) in subsection (b)—

(i) in paragraph (1), by inserting

“(other than subsections (a) and (b) of section 2799A–11)” after “part D”; and

(ii) in paragraph (2)(A), by inserting

“(other than subsections (a) and (b) of section 2799A–11)” after “part D”; and

(iii) in paragraph (2)(C)(ii), by inserting

“(other than subsections (a) and (b) of section 2799A–11)” after “part D”.

(b) ERISA.—

(1) IN GENERAL.—Subtitle B of title I of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1021 et seq.) is amended—

(A) in subpart B of part 7 (29 U.S.C. 1185 et seq.), by adding at the end the fol-
SEC. 726. OVERSIGHT OF PHARMACY BENEFIT MANAGER SERVICES.

(a) IN GENERAL.—For plan years beginning on or after the date that is 2 years after the date of enactment of this section, a group health plan or a health insurance issuer offering group health insurance coverage, or an entity or subsidiary providing pharmacy benefits management services on behalf of such a plan or issuer, shall not enter into a contract with a drug manufacturer, distributor, wholesaler, subcontractor, rebate aggregator, or any other third party that limits (or delays beyond the applicable reporting period described in subsection (b)(1)) the disclosure of information to plan sponsors in such a manner that prevents such plan, issuer, or entity from making the reports described in subsection (b).

(b) REPORTS.—

“(1) IN GENERAL.—With respect to plan years beginning on or after the date that is 2 years after the date of enactment of this section, not less frequently than every 6 months (or at the request of a plan sponsor, not less frequently than quarterly, but under the same conditions, terms, and cost of the semiannual report under this subsection), a group health plan or health insurance issuer offering group health insurance coverage, or an entity providing pharmacy benefits management services on
behalf of such a plan or issuer, shall submit to the
plan sponsor (as defined in section 3(16)(B)) of
such plan or coverage a report in accordance with
this section. Each such report shall be made avail-
able to such plan sponsor in a machine-readable for-
mat and shall include the information described in
paragraph (2).

“(2) INFORMATION DESCRIBED.—For purposes
of paragraph (1), the information described in this
paragraph is, with respect to drugs covered by a
group health plan or health insurance issuer offering
group health insurance coverage during each report-
ing period—

“(A) a list of drugs for which a claim was
filed and, with respect to each such drug on
such list—

“(i) the brand name, chemical entity,
and National Drug Code;

“(ii) the type of dispensing channel
used to furnish such drug, including retail,
mail order, or specialty pharmacy;

“(iii) with respect to each drug dis-
pensed under each type of dispensing chan-
nel (including retail, mail order, or spe-
cialty pharmacy)—
“(I) whether such drug is a brand name drug or a generic drug, and—

“(aa) in the case of a brand name drug, the wholesale acquisition cost, listed as cost per days supply and cost per dosage unit, on the date such drug was dispensed; and

“(bb) in the case of a generic drug, the average wholesale price, listed as cost per days supply and cost per dosage unit, on the date such drug was dispensed; and

“(II) the total number of—

“(aa) prescription claims (including original prescriptions and refills);

“(bb) participants, beneficiaries, and enrollees for whom a claim for such drug was filed;

“(cc) dosage units per fill of such drug; and
“(dd) days supply of such

drug per fill;

“(iv) the net price per course of treatment or single fill, such as a 30-day supply or 90-day supply to the plan or coverage after manufacturer rebates, fees, and other remuneration or adjustments;

“(v) the total amount of out-of-pocket spending by participants, beneficiaries, and enrollees on such drug, including spending through copayments, coinsurance, and deductibles;

“(vi) the total net spending by the plan or coverage;

“(vii) total amount received, or expected to be received, by the plan or coverage from any entity in drug manufacturer rebates, fees, alternative discounts, and all other remuneration received from an entity or any third party (including group purchasing organizations) other than the plan sponsor;

“(viii) the total amount received, or expected to be received by the plan or issuer, from drug manufacturers in re-
bates, fees, alternative discounts, or other remuneration—

“(I) that has been paid, or is to be paid, by drug manufacturers for claims incurred during the reporting period; and

“(II) that is related to utilization rebates for such drug; and

“(ix) to the extent feasible, information on the total amount of remuneration, including copayment assistance dollars paid, copayment cards applied, or other discounts provided by each drug manufacturer (or entity administering copay assistance on behalf of such drug manufacturer) to the participants, beneficiaries, and enrollees enrolled in such plan or coverage;

“(B) for each category or class of drugs for which a claim was filed, a breakdown of the total gross spending on drugs in such category or class before rebates, price concessions, alternative discounts, or other remuneration from drug manufacturers, and the net spending after such rebates, price concessions, alternative dis-
counts, or other remuneration from drug manufacturers, including—

“(i) the number of participants, beneficiaries, and enrollees who filled a prescription for a drug in such category or class, including the National Drug Code for each such drug;

“(ii) if applicable, a description of the formulary tiers and utilization mechanisms (such as prior authorization or step therapy) employed for drugs in that category or class; and

“(iii) the total out-of-pocket spending under the plan or coverage by participants, beneficiaries, and enrollees, including spending through copayments, coinsurance, and deductibles;

“(C) in the case of a drug for which gross spending by such plan, coverage, or entity exceeded $10,000 during the reporting period—

“(i) a list of all other drugs in the same therapeutic category or class; and

“(ii) the rationale for the formulary placement of such drug in that therapeutic category or class, if applicable;
“(D) amounts paid directly or indirectly in
rebates, fees, or any other type of compensation
(as defined in section 408(b)(2)(B)(ii)(dd)(AA))
to brokers, consultants, advisors, or any other
individual or firm, for the referral of the group
health plan’s or health insurance issuer’s busi-
ness to an entity providing pharmacy benefits
management services, including the identity of
the recipient of such amounts;

“(E) an explanation of any benefit design
parameters that encourage or require partici-
pants, beneficiaries, and enrollees in such plan
or coverage to fill prescriptions at mail order,
specialty, or retail pharmacies that are affili-
ated with or under common ownership with the
entity providing pharmacy benefit management
services under such plan or coverage, including
mandatory mail and specialty home delivery
programs, retail and mail auto-refill programs,
and cost-sharing assistance incentives directly
or indirectly funded by such entity; and

“(F) in the case of a plan or coverage (or
an entity providing pharmacy benefits manage-
ment services on behalf of such plan or cov-
verage) that has an affiliated pharmacy or pharmacy under common ownership—

“(i) the percentage of total prescriptions dispensed by such pharmacies to individuals enrolled in such plan or coverage;

“(ii) a list of all drugs dispensed by such pharmacies to individuals enrolled in such plan or coverage, and, with respect to each drug dispensed—

“(I) the amount charged, per dosage unit, per 30-day supply, or per 90-day supply (as applicable) to the plan or issuer, and to participants, beneficiaries, and enrollees enrolled in such plan or coverage;

“(II) the median amount charged to such plan or issuer, and the interquartile range of the costs, per dosage unit, per 30-day supply, and per 90-day supply, including amounts paid by the participants, beneficiaries, and enrollees, when the same drug is dispensed by other pharmacies that are not affiliated with or under common ownership with the entity and that are
included in the pharmacy network of such plan or coverage;

“(III) the lowest cost per dosage unit, per 30-day supply and per 90-day supply, for each such drug, including amounts charged to the plan and participants, beneficiaries, and enrollees, that is available from any pharmacy included in the network of such plan or coverage; and

“(IV) the net acquisition cost per dosage unit, per 30-day supply, and per 90-day supply, if such drug is subject to a maximum price discount.

“(3) PRIVACY REQUIREMENTS.—Health insurance issuers offering group health insurance coverage and entities providing pharmacy benefits management services on behalf of a group health plan shall provide information under paragraph (1) in a manner consistent with the privacy, security, and breach notification regulations promulgated under section 13402(a) of the Health Information Technology for Clinical Health Act, and shall restrict the use and disclosure of such information according to such privacy regulations.
“(4) Disclosure and redisclosure.—

“(A) Limitation to business associates.—A plan sponsor receiving a report under paragraph (1) may disclose such information only to the entity from which the report was received, the group health plan for which the report pertains, or to that entity’s business associates as defined in section 160.103 of title 45, Code of Federal Regulations (or successor regulations) or as permitted by the HIPAA Privacy Rule (45 CFR parts 160 and 164, subparts A and E).

“(B) Clarification regarding public disclosure of information.—Nothing in this section shall prevent a group health plan or health insurance issuer offering group health insurance coverage, or an entity providing pharmacy benefits management services on behalf of such a plan or coverage, from placing reasonable restrictions on the public disclosure of the information contained in a report described in paragraph (1), except that such plan, issuer, or entity may not restrict disclosure of such report to the Department of Health and Human Services, the Department of Labor, the Department
of the Treasury, or the Comptroller General of
the United States.

“(C) LIMITED FORM OF REPORT.—The
Secretary shall define through rulemaking a
limited form of the report under paragraph (1)
required of plan sponsors who are drug manu-
facturers, drug wholesalers, or other direct par-
ticipants in the drug supply chain, in order to
prevent anti-competitive behavior.

“(5) REPORT TO GAO.—A group health plan or
health insurance issuer offering group health insur-
ance coverage, or an entity providing pharmacy ben-
efits management services on behalf of such plan or
coverage, shall submit to the Comptroller General of
the United States each of the first 4 reports sub-
mitted to a plan sponsor under paragraph (1) and
other such reports as requested, in accordance with
the privacy requirements under paragraph (3), the
disclosure and redisclosure standards under para-
graph (4), the standards specified pursuant to para-
graph (6), and such other information that the
Comptroller General determines necessary to carry
out the study under section 106(d) of the Lower
Costs, More Transparency Act.
“(6) STANDARD FORMAT.—Not later than 1 year after the date of enactment of this section, the Secretary shall specify through rulemaking standards for group health plans, health insurance issuers offering group health insurance coverage, and entities providing pharmacy benefits management services on behalf of such plans or coverage, required to submit reports under paragraph (1) to submit such reports in a standard format.

“(c) RULE OF CONSTRUCTION.—Nothing in this section shall be construed to permit a group health plan, health insurance issuer, or entity providing pharmacy benefits management services on behalf of such plan or coverage, to restrict disclosure to, or otherwise limit the access of, the Secretary of Labor to a report described in subsection (b)(1) or information related to compliance with subsections (a) or (b) by entities subject to such subsection.

“(d) DEFINITION.—In this section, the term ‘whole-sale acquisition cost’ has the meaning given such term in section 1847A(c)(6)(B) of the Social Security Act.’’

(B) in section 502 (29 U.S.C. 1132)—

(i) in subsection (b)(3), by striking “under subsection (c)(9))” and inserting
“under paragraphs (9) and (13) of subsection (c)”; and

(ii) in subsection (c), by adding at the end the following new paragraph:

“(13) SECRETARIAL ENFORCEMENT AUTHORITY RELATING TO OVERSIGHT OF PHARMACY BENEFITS MANAGER SERVICES.—

“(A) FAILURE TO PROVIDE TIMELY INFORMATION.—The Secretary may impose a penalty against any health insurance issuer or entity providing pharmacy benefits management services that violates section 726(a) or fails to provide information required under section 726(b) in the amount of $10,000 for each day during which such violation continues or such information is not disclosed or reported.

“(B) FALSE INFORMATION.—The Secretary may impose a penalty against a health insurance issuer or entity providing pharmacy benefits management services that knowingly provides false information under section 726 in an amount not to exceed $100,000 for each item of false information. Such penalty shall be in addition to other penalties as may be prescribed by law.
“(C) WAIVERS.—The Secretary may waive penalties under subparagraph (A), or extend the period of time for compliance with a requirement of section 726, for an entity in violation of such section that has made a good-faith effort to comply with such section.”.

(2) CLERICAL AMENDMENT.—The table of contents in section 1 of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1001 et seq.) is amended by inserting after the item relating to section 725 the following new item:

“Sec. 726. Oversight of pharmacy benefits manager services.”.

(c) IRC.—

(1) IN GENERAL.—Subchapter B of chapter 100 of the Internal Revenue Code of 1986 is amended by adding at the end the following:

“SEC. 9826. OVERSIGHT OF PHARMACY BENEFIT MANAGER SERVICES.

“(a) IN GENERAL.—For plan years beginning on or after the date that is 2 years after the date of enactment of this section, a group health plan, or an entity or subsidiary providing pharmacy benefits management services on behalf of such a plan, shall not enter into a contract with a drug manufacturer, distributor, wholesaler, subcontractor, rebate aggregator, or any other third party that limits (or delays beyond the applicable reporting period de-
scribed in subsection (b)(1)) the disclosure of information
to plan sponsors in such a manner that prevents such plan
or entity from making the reports described in subsection
(b).

“(b) REPORTS.—

“(1) IN GENERAL.—With respect to plan years
beginning on or after the date that is 2 years after
the date of enactment of this section, not less fre-
quently than every 6 months (or at the request of
a plan sponsor, not less frequently than quarterly,
but under the same conditions, terms, and cost of
the semiannual report under this subsection), a
group health plan, or an entity providing pharmacy
benefits management services on behalf of such a
plan, shall submit to the plan sponsor (as defined in
section 3(16)(B) of the Employee Retirement In-
come Security Act of 1974) of such plan a report in
accordance with this section. Each such report shall
be made available to such plan sponsor in a ma-
cine-readable format and shall include the informa-
tion described in paragraph (2).

“(2) INFORMATION DESCRIBED.—For purposes
of paragraph (1), the information described in this
paragraph is, with respect to drugs covered by a
group health plan during each reporting period—
“(A) a list of drugs for which a claim was filed and, with respect to each such drug on such list—

“(i) the brand name, chemical entity, and National Drug Code;

“(ii) the type of dispensing channel used to furnish such drug, including retail, mail order, or specialty pharmacy;

“(iii) with respect to each drug dispensed under each type of dispensing channel (including retail, mail order, or specialty pharmacy)—

“(I) whether such drug is a brand name drug or a generic drug, and—

“(aa) in the case of a brand name drug, the wholesale acquisition cost, listed as cost per days supply and cost per dosage unit, on the date such drug was dispensed; and

“(bb) in the case of a generic drug, the average wholesale price, listed as cost per days supply and cost per dosage unit, on
the date such drug was dispensed; and

“(II) the total number of—

“(aa) prescription claims (including original prescriptions and refills);

“(bb) participants and beneficiaries for whom a claim for such drug was filed;

“(cc) dosage units per fill of such drug; and

“(dd) days supply of such drug per fill;

“(iv) the net price per course of treatment or single fill, such as a 30-day supply or 90-day supply to the plan after manufacturer rebates, fees, and other remuneration or adjustments;

“(v) the total amount of out-of-pocket spending by participants and beneficiaries on such drug, including spending through copayments, coinsurance, and deductibles;

“(vi) the total net spending by the plan;
“(vii) total amount received, or expected to be received, by the plan from any entity in drug manufacturer rebates, fees, alternative discounts, and all other remuneration received from an entity or any third party (including group purchasing organizations) other than the plan sponsor;

“(viii) the total amount received, or expected to be received, by the plan from drug manufacturers in rebates, fees, alternative discounts, or other remuneration—

“(I) that has been paid, or is to be paid, by drug manufacturers for claims incurred during the reporting period; and

“(II) that is related to utilization rebates for such drug; and

“(ix) to the extent feasible, information on the total amount of remuneration, including copayment assistance dollars paid, copayment cards applied, or other discounts provided by each drug manufacturer (or entity administering copay assistance on behalf of such drug manufacturer)
to the participants and beneficiaries enrolled in such plan;

“(B) for each category or class of drugs for which a claim was filed, a breakdown of the total gross spending on drugs in such category or class before rebates, price concessions, alternative discounts, or other remuneration from drug manufacturers, and the net spending after such rebates, price concessions, alternative discounts, or other remuneration from drug manufacturers, including—

“(i) the number of participants and beneficiaries who filled a prescription for a drug in such category or class, including the National Drug Code for each such drug;

“(ii) if applicable, a description of the formulary tiers and utilization mechanisms (such as prior authorization or step therapy) employed for drugs in that category or class; and

“(iii) the total out-of-pocket spending under the plan by participants and beneficiaries, including spending through copayments, coinsurance, and deductibles;
“(C) in the case of a drug for which gross spending by such plan or entity exceeded $10,000 during the reporting period—

“(i) a list of all other drugs in the same therapeutic category or class; and

“(ii) the rationale for the formulary placement of such drug in that therapeutic category or class, if applicable;

“(D) amounts paid directly or indirectly in rebates, fees, or any other type of compensation (as defined in section 408(b)(2)(B)(ii)(dd)(AA) of the Employee Retirement Income Security Act) to brokers, consultants, advisors, or any other individual or firm, for the referral of the group health plan’s business to an entity providing pharmacy benefits management services, including the identity of the recipient of such amounts;

“(E) an explanation of any benefit design parameters that encourage or require participants, beneficiaries, and enrollees in such plan to fill prescriptions at mail order, specialty, or retail pharmacies that are affiliated with or under common ownership with the entity providing pharmacy benefit management services
under such plan, including mandatory mail and
specialty home delivery programs, retail and
mail auto-refill programs, and cost-sharing as-
sistance incentives directly or indirectly funded
by such entity; and

“(F) in the case of a plan (or an entity
providing pharmacy benefits management serv-
ices on behalf of such plan) that has an affili-
ated pharmacy or pharmacy under common
ownership—

“(i) the percentage of total prescrip-
tions dispensed by such pharmacies to in-
dividuals enrolled in such plan;

“(ii) a list of all drugs dispensed by
such pharmacies to individuals enrolled in
such plan and, with respect to each drug
dispensed—

“(I) the amount charged, per
dosage unit, per 30-day supply, or per
90-day supply (as applicable) to the
plan and to participants and bene-
fi ciaries enrolled in such plan;

“(II) the median amount charged
to such plan, and the interquartile
range of the costs, per dosage unit,
per 30-day supply, and per 90-day supply, including amounts paid by the participants and beneficiaries, when the same drug is dispensed by other pharmacies that are not affiliated with or under common ownership with the entity and that are included in the pharmacy network of such plan;

“(III) the lowest cost per dosage unit, per 30-day supply and per 90-day supply, for each such drug, including amounts charged to the plan and to participants and beneficiaries, that is available from any pharmacy included in the network of such plan;

and

“(IV) the net acquisition cost per dosage unit, per 30-day supply, and per 90-day supply, if such drug is subject to a maximum price discount.

“(3) PRIVACY REQUIREMENTS.—Health insurance issuers offering group health insurance coverage and entities providing pharmacy benefits management services on behalf of a group health plan shall provide information under paragraph (1) in a
manner consistent with the privacy, security, and
breach notification regulations promulgated under
section 13402(a) of the Health Information Tech-
ology for Clinical Health Act, and shall restrict the
use and disclosure of such information according to
such privacy regulations.

“(4) Disclosure and Redisclosure.—

“(A) Limitation to Business Associates.—A plan sponsor receiving a report under
paragraph (1) may disclose such information
only to the entity from which the report was re-
ceived, the group health plan for which the re-
port pertains, or to that entity’s business asso-
ciates as defined in section 160.103 of title 45,
Code of Federal Regulations (or successor regu-
lations) or as permitted by the HIPAA Privacy
Rule (45 CFR parts 160 and 164, subparts A
and E).

“(B) Clarification Regarding Public
Disclosure of Information.—Nothing in
this section shall prevent a group health plan or
health insurance issuer offering group health
insurance coverage, or an entity providing phar-
my benefits management services on behalf of
such a plan or coverage, from placing reason-
able restrictions on the public disclosure of the information contained in a report described in paragraph (1), except that such plan, issuer, or entity may not restrict disclosure of such report to the Department of Health and Human Services, the Department of Labor, the Department of the Treasury, or the Comptroller General of the United States.

“(C) LIMITED FORM OF REPORT.—The Secretary shall define through rulemaking a limited form of the report under paragraph (1) required of plan sponsors who are drug manufacturers, drug wholesalers, or other direct participants in the drug supply chain, in order to prevent anti-competitive behavior.

“(5) REPORT TO GAO.—A group health plan, or an entity providing pharmacy benefits management services on behalf of such plan, shall submit to the Comptroller General of the United States each of the first 4 reports submitted to a plan sponsor under paragraph (1) and other such reports as requested, in accordance with the privacy requirements under paragraph (3), the disclosure and redisclosure standards under paragraph (4), the standards specified pursuant to paragraph (6), and such other informa-
tion that the Comptroller General determines neces-

sary to carry out the study under section 106(d)

“(6) STANDARD FORMAT.—Not later than 1
year after the date of enactment of this section, the
Secretary shall specify through rulemaking stand-
ards for group health plans, and entities providing
pharmacy benefits management services on behalf of
such plans, required to submit reports under para-
graph (1) to submit such reports in a standard for-
mat.

“(c) RULE OF CONSTRUCTION.—Nothing in this sec-
tion shall be construed to permit a group health plan or
entity providing pharmacy benefits management services
on behalf of such plan, to restrict disclosure to, or other-
wise limit the access of, the Secretary of Health and
Human Services to a report described in subsection (b)(1)
or information related to compliance with subsections (a)
or (b) by entities subject to such subsection.

“(d) DEFINITION.—In this section, the term ‘whole-
sale acquisition cost’ has the meaning given such term in
section 1847A(c)(6)(B) of the Social Security Act.”.

(2) CLERICAL AMENDMENT.—The table of sec-
tions for subchapter B of chapter 100 of the Inter-
nal Revenue Code of 1986 is amended by adding at the end the following new item:

“Sec. 9826. Oversight of pharmacy benefits manager services.”

(d) GAO REPORTS.—

(1) REPORT ON PHARMACY NETWORK DESIGN.—

(A) IN GENERAL.—Not later than 3 years after the date of enactment of this Act, the Comptroller General of the United States shall submit to Congress a report on—

(i) pharmacy networks that have contracted with group health plans, health insurance issuers offering group health insurance coverage, or entities providing pharmacy benefits management services on behalf of such plans or issuers, including networks with pharmacies that are under common ownership (in whole or part) with such plans, issuers, or entities (including entities that provide pharmacy benefits administrative services on behalf of such plans or issuers);

(ii) pharmacy network design parameters that encourage individuals enrolled in such plans or coverage to fill prescriptions at mail order, specialty, or retail phar-
macies that are wholly or partially-owned
by a plan, issuer, or entity;

(iii) whether such plans and issuers
have options to elect different network
pricing arrangements in the marketplace
with entities that provide pharmacy bene-
fits management services and the preva-
ience of electing such different network
pricing arrangements;

(iv) with respect to pharmacy net-
works that include pharmacies under com-
mon ownership described in clause (i)—

(I) whether such networks are
designed to encourage individuals en-
rolled in a group health plan or health
insurance coverage to use such phar-
macies over other network pharmacies
for specific services or drugs, and if
so, the reasons the networks give for
encouraging use of such pharmacies;
and

(II) whether such pharmacies are
used by enrollees disproportionately
more in the aggregate or for specific
services or drugs compared to other network pharmacies;

(v) the degree to which mail order, specialty, or retail pharmacies that dispense prescription drugs to an enrollee in a plan or coverage that are under common ownership (in whole or part) with plans, issuers, or entities providing pharmacy benefits management services or pharmacy benefits administrative services on behalf of such plan or coverage receive reimbursement that is greater than the median price charged to the plan or issuer when the same drug is dispensed to enrollees in the plan or coverage by other pharmacies included in the pharmacy network of that plan, issuer, or entity that are not wholly or partially owned by the plan or issuer, or entity providing pharmacy benefits management services on behalf of such plan or issuer.

(B) REQUIREMENT.—The Comptroller General of the United States shall ensure that the report under subparagraph (A) does not contain information that would identify a spe-
specific group health plan or health insurance issuer (or an entity providing pharmacy benefits management services on behalf of such plan or issuer), or otherwise contain commercial or financial information that is privileged or confidential.

(C) DEFINITIONS.—In this paragraph, the terms “group health plan”, “health insurance coverage”, and “health insurance issuer” have the meanings given such terms in section 2791 of the Public Health Service Act (42 U.S.C. 300gg–91).

(2) REPORT ON COPAY ASSISTANCE PROGRAMS.—Not later than 18 months after the date of the enactment of this Act, the Comptroller General of the United States shall submit to Congress a report on what is known about the role of copay assistance programs and the impact of such programs on commercial health insurance, stop loss, and drug prices. Such report shall include to the extent feasible—

(A) a description of copay assistance programs, including—

(i) the types of programs available and the methods of providing copay assist-
ance through such programs, including cash discounts, copay cards, or drugs provided to an individual at no cost;

(ii) how such programs are funded;

(iii) the types of entities that own, operate, or otherwise conduct such programs, the types of information such entities collect, and the direct and indirect contractual relationships between the entities in the drug supply chain that interact with such programs, such as a drug manufacturer, pharmacy, wholesaler, switch, rebate aggregator, pharmacy benefit manager, and other entities in the drug supply chain;

(iv) the effect of such programs on patient out-of-pocket spending, including for stop-loss insurance, and drug utilization, including drug adherence; and

(v) patient eligibility criteria for such programs; and

(B) an analysis of—

(i) the sources of funding for such programs; and

(ii) the effects of such programs on Federal health care programs and the indi-
individuals enrolled in such Federal health care programs.

SEC. 107. REPORTS ON HEALTH CARE TRANSPARENCY TOOLS AND DATA.

(a) INITIAL REPORT.—Not later than December 31, 2024, the Comptroller General of the United States shall submit to the Committees (as defined in subsection (d)) an initial report that—

(1) identifies and describes health care transparency tools and Federal health care reporting requirements (as described in subsection (d)) that are in effect as of the date of the submission of such initial report, including the frequency of reports with respect to each such requirement and whether any such requirements are duplicative;

(2) reviews how such reporting requirements are enforced;

(3) analyzes whether the public availability of health care transparency tools, and the publication of data pursuant to such reporting requirements, has—

(A) been utilized and valued by consumers, including reasons for such utilization (or lack thereof); and
(B) assisted health insurance plan sponsors and fiduciaries improve benefits, lower health care costs for plan participants, and meet fiduciary requirements;

(4) includes recommendations to the Committees, the Secretary of Health and Human Services, the Secretary of Labor, and the Secretary of the Treasury to—

(A) improve the efficiency, accuracy, and usability of health care transparency tools;

(B) streamline Federal health care reporting requirements to eliminate duplicative requirements and reduce the burden on entities required to submit reports pursuant to such provisions;

(C) improve the accuracy and efficiency of such reports while maintaining the integrity and usability of the data provided by such reports;

(D) address any gaps in data provided by such reports; and

(E) ensure that the data and information reported is comparable and usable to consumers, including patients, plan sponsors, and policy makers.
(b) **FINAL REPORT.**—Not later than December 31, 2028, the Comptroller General of the United States shall submit to the Committees a report that includes—

(1) the information provided in the initial report, along with any updates to such information; and

(2) any new information with respect to health care transparency tools that have been released following the submission of such initial report, or new reporting requirements in effect as of the date of the submission of the final report.

(c) **REPORT ON EXPANDING PRICE TRANSPARENCY REQUIREMENTS.**—Not later than December 31, 2025, the Comptroller General of the United States, in consultation with the Secretary of Health and Human Services, health care provider groups, and patient advocacy groups, shall submit to the Committees a report that includes recommendations to expand price transparency reporting requirements to additional care settings, with an emphasis on settings where shoppable services (as defined in subsection (d)) are furnished.

(d) **DEFINITIONS.**—In this section:

(1) **COMMITTEES.**—The term “Committees” means the Committee on Ways and Means, the Committee on Energy and Commerce, and the Com-
mittee on Education and the Workforce of the House of Representatives, and the Committee on Fi-

nance and the Committee on Health, Education, Labor, and Pensions of the Senate.

(2) FEDERAL HEALTH CARE REPORTING RE-

QUIREMENTS.—The term “Federal health care re-

porting requirements” includes regulatory and statu-

tory requirements with respect to the reporting and publication of health care price, cost access, and quality data, including requirements established by the Consolidated Appropriations Act of 2021 (Public Law 116–260), this Act, and other reporting and publication requirements with respect to trans-
parency in health care as identified by the Comptroller General of the United States.

(3) SHoppable service.—The term “shoppable service” means a service that can be scheduled by a health care consumer in advance and includes all ancillary items and services customarily furnished as part of such service.

SEC. 108. REPORT ON INTEGRATION IN MEDICARE.

(a) REQUIRED MA AND PDP REPORTING.—

(1) MA PLANS.—Section 1857(e) of the Social Security Act (42 U.S.C. 1395w–27(e)) is amended by adding at the end the following new paragraph:
“(6) REQUIRED DISCLOSURE OF CERTAIN INFORMATION RELATING TO HEALTH CARE PROVIDER OWNERSHIP.—

“(A) IN GENERAL.—For plan year 2025 and for every third plan year thereafter, each applicable MA organization offering an MA plan under this part during such plan year shall submit to the Secretary, at a time and in a manner specified by the Secretary—

“(i) the taxpayer identification number for each health care provider that was a specified health care provider with respect to such organization during such year;

“(ii) the total amount of incentive-based payments made to, and the total amount of shared losses recoupments collected from, such specified health care providers during such plan year; and

“(iii) the total amount of incentive-based payments made to, and the total amount of shared losses recoupments collected from, providers of services and suppliers not described in clause (ii) during such plan year.
“(B) DEFINITIONS.—For purposes of this paragraph:

“(i) APPLICABLE MA ORGANIZATION.—The term ‘applicable MA organization’ means, with respect to a plan year, an MA organization with at least 25,000 individuals enrolled under Medicare Advantage plans offered by such organization during such plan year.

“(ii) SPECIFIED HEALTH CARE PROVIDER.—The term ‘specified health care provider’ means, with respect to an applicable MA organization and a plan year, a provider of services or supplier with respect to which such organization (or any person with an ownership or control interest (as defined in section 1124(a)(3)) in such organization) is a person with an ownership or control interest (as so defined).”.

(2) PRESCRIPTION DRUG PLANS.—Section 1860D–12(b) of the Social Security Act (42 U.S.C. 1395w–112(b)) is amended by adding at the end the following new paragraph:
“(9) Provision of information relating to pharmacy ownership.—

“(A) In general.—For plan year 2025 and for every third plan year thereafter, each PDP sponsor offering a prescription drug plan under this part during such plan year shall submit to the Secretary, at a time and in a manner specified by the Secretary, the taxpayer identification number and National Provider Identifier for each pharmacy that was a specified pharmacy with respect to such sponsor during such year.

“(B) Definition.—For purposes of this paragraph, the term ‘specified pharmacy’ means, with respect to an PDP sponsor offering a prescription drug plan and a plan year, a pharmacy with respect to which—

“(i) such sponsor (or any person with an ownership or control interest (as defined in section 1124(a)(3)) in such sponsor) is a person with an ownership or control interest (as so defined); or

“(ii) a pharmacy benefit manager offering services under such plan (or any person with an ownership or control inter-
est (as so defined) in such sponsor) is a person with an ownership or control interest (as so defined).”.

(b) MedPAC Reports.—Part E of title XVIII of the Social Security Act (42 U.S.C. 1395x et seq.), as amended by section 101, is further amended by adding at the end the following new section:

“SEC. 1899D. REPORTS ON VERTICAL INTEGRATION UNDER MEDICARE.

“(a) In General.—Not later than June 15, 2029, and every 3 years thereafter, the Medicare Payment Advisory Commission shall submit to Congress a report on the state of vertical integration in the health care sector during the applicable year with respect to entities participating in the Medicare program, including health care providers, pharmacies, prescription drug plan sponsors, Medicare Advantage organizations, and pharmacy benefit managers. Such report shall include—

“(1) with respect to Medicare Advantage organizations, the evaluation described in subsection (b);

“(2) with respect to prescription drug plans, pharmacy benefit managers, and pharmacies, the comparisons and evaluations described in subsection (c);
“(3) with respect to Medicare Advantage plans under which benefits are available for physician-administered drugs, the information described in subsection (d); and

“(4) the identifications described in subsection (e); and

“(5) an analysis of the impact of such integration on health care access, price, quality, and outcomes.

“(b) MEDICARE ADVANTAGE ORGANIZATIONS.—For purposes of subsection (a)(1), the evaluation described in this subsection is, with respect to Medicare Advantage organizations and an applicable year, an evaluation, taking into account patient acuity and the types of areas serviced by such organization, of—

“(1) the average number of qualifying diagnoses made during such year with respect to enrollees of a Medicare Advantage plan offered by such organization who, during such year, received a health risk assessment from a specified health care provider;

“(2) the average risk score for such enrollees who received such an assessment during such year;

“(3) any relationship between such risk scores for such enrollees receiving such an assessment from
such a provider during such year and incentive payments made to such providers;

“(4) the average risk score for enrollees of such plan who received any item or service from a specified health care provider during such year;

“(5) any relationship between the risk scores of enrollees under such plan and whether the enrollees have received any item or service from a specified provider; and

“(6) any relationship between the risk scores of enrollees under such plan that have received any item or service from a specified provider and incentive payments made under the plan to specified providers.

“(c) PRESCRIPTION DRUG PLANS.—For purposes of subsection (a)(2), the comparisons and evaluations described in this subsection are, with respect to prescription drug plans and an applicable year, the following:

“(1) For each covered part D drug for which benefits are available under such a plan, a comparison of the average negotiated rate in effect with specified pharmacies with such rates in effect for in-network pharmacies that are not specified pharmacies.

“(2) Comparisons of the following:
“(A) The total amount paid by pharmacy benefit managers to specified pharmacies for covered part D drugs and the total amount so paid to pharmacies that are not specified pharmacies for such drugs.

“(B) The total amount paid by such sponsors to specified pharmacy benefit managers as reimbursement for covered part D drugs and the total amount so paid to pharmacy benefit managers that are not specified pharmacy benefit managers as such reimbursement.

“(C) Fees paid under by plan to specified pharmacy benefit managers compared to such fees paid to pharmacy benefit managers that are not specified pharmacy benefit managers.

“(3) An evaluation of the total amount of direct and indirect remuneration for covered part D drugs passed through to prescription drug plan sponsors and the total amount retained by pharmacy benefit managers (including entities under contract with such a manager).

“(4) To the extent that the available data permits, an evaluation of fees charged by rebate aggregators that are affiliated with plan sponsors.
“(d) PHYSICIAN-ADMINISTERED DRUGS.—For purposes of subsection (a)(3), the information described in this subsection is, with respect to physician-administered drugs for which benefits are available under a Medicare Advantage plan during an applicable year, the following:

“(1) With respect to each such plan, an identification of each drug for which benefits were available under such plan only when administered by a health care provider that acquired such drug from an affiliated pharmacy.

“(2) An evaluation of the difference between the total number of drugs administered by a health care provider that were acquired from affiliated pharmacies compared to the number of such drugs so administered that were acquired from pharmacies other than affiliated pharmacies, and an evaluation of the difference in payments for such drugs so administered when acquired from a specified pharmacy and when acquired from a pharmacy that is not a specified pharmacy.

“(3) An evaluation of the dollar value of all such drugs that were not so administered because of a delay attributable to an affiliated pharmacy compared to the dollar value of all such drugs that were
not so administered because of a delay attributable to pharmacy that is not an affiliated pharmacy.

“(4) The number of enrollees administered such a drug that was acquired from an affiliated pharmacy.

“(5) The number of enrollees furnished such a drug that was acquired from a pharmacy that is not an affiliated pharmacy.

“(e) IDENTIFICATIONS.—For purposes of subsection (a)(4), the identifications described in this subsection are, with respect to an applicable year, identifications of each health care entity participating under the Medicare program with respect to which another health care entity so participating is a person with an ownership or control interest (as defined in section 1124(a)(3)).

“(f) DEFINITIONS.—In this section:

“(1) AFFILIATED PHARMACY.—The term ‘affiliated pharmacy’ means, with respect to a Medicare Advantage plan offered by a Medicare Advantage organization, a pharmacy with respect to which such organization (or any person with an ownership or control interest (as defined in section 1124(a)(3)) in such organization) is a person with an ownership or control interest (as so defined).
'"(2) Applicable year.—The term ‘applicable year’ means, with respect to a report submitted under subsection (a), the first calendar year beginning at least 4 years prior to the date of the submission of such report.

"(3) Covered part D drug.—The term ‘covered part D drug’ has the meaning given such term in section 1860D–2(e).

"(4) Direct and indirect remuneration.—The term ‘direct and indirect remuneration’ has the meaning given such term in section 423.308 of title 42, Code of Federal Regulations (or any successor regulation).

"(5) Qualifying diagnosis.—The term ‘qualifying diagnosis’ means, with respect to an enrollee of a Medicare Advantage plan, a diagnosis that is taken into account in calculating a risk score for such enrollee under the risk adjustment methodology established by the Secretary pursuant to section 1853(a)(3).

"(6) Risk score.—The term ‘risk score’ means, with respect to an enrollee of a Medicare Advantage plan, the score calculated for such individual using the methodology described in paragraph (5).
“(7) PHYSICIAN-ADMINISTERED DRUG.—The term ‘physician-administered drug’ means a drug furnished to an individual that, had such individual been enrolled under part B and not enrolled under part C, would have been payable under section 1842(o).

“(8) SPECIFIED HEALTH CARE PROVIDER.—The term ‘specified health care provider’ means, with respect to a Medicare Advantage plan offered by a Medicare Advantage organization, a health care provider with respect to which such organization (or any person with an ownership or control interest (as defined in section 1124(a)(3)) in such organization) is a person with an ownership or control interest (as so defined).

“(9) SPECIFIED PHARMACY.—The term ‘specified pharmacy’ means, with respect to a prescription drug plan offered by a prescription drug plan sponsor, a pharmacy with respect to which—

“(A) such sponsor (or any person with an ownership or control interest (as defined in section 1124(a)(3)) in such sponsor) is a person with an ownership or control interest (as so defined); or
“(B) a pharmacy benefit manager offering services under such plan (or any person with an ownership or control interest (as so defined) in such sponsor) is a person with an ownership or control interest (as so defined).

“(10) SPECIFIED PHARMACY BENEFIT MANAGER.—The term ‘specified pharmacy benefit manager’ means, with respect to a prescription drug plan offered by a prescription drug plan sponsor, a pharmacy benefit manager with respect to which such sponsor (or any person with an ownership or control interest (as defined in section 1124(a)(3)) in such sponsor) is a person with an ownership or control interest (as so defined).”.

SEC. 109. ADVISORY COMMITTEE.

(a) In General.—Not later than January 1, 2025, the Secretary of Labor, the Secretary of Health and Human Services, and the Secretary of the Treasury shall jointly convene an advisory committee (in this section referred to as the “committee”) consisting of 9 members to advise the Secretaries on how to improve the usefulness, accessibility, and usability of information made available in accordance the amendments made by sections 105 and 106, and by section 204 of division BB of the Consolidated
Appropriation Act, 2021 (Public Law 116–260), streamline the reporting of such information, and ensure that—

(1) such information is accurate, accessible, and is delivered in a form and manner consistent with the requirements of such section;

(2) the form and manner in which such information is delivered is routinely updated in accordance with widely-used practices in order to ensure accessibility; and

(3) such information is available for audit (including by making recommendations relating to how Federal and State actors may conduct such audits).

(b) Membership.—The Secretaries shall jointly appoint members representing end-users of the information described in subsection (a). Vacancies on the committee shall be filled by appointment consistent with this subsection not later than 3 months after the vacancy arises.

(c) Termination.—The committee shall terminate on January 1, 2028.

(d) Nonapplication of FACA.—The Federal Advisory Committee Act (5 U.S.C. App.) shall not apply to the committee.
SEC. 110. REPORT ON IMPACT OF MEDICARE REGULATIONS ON PROVIDER AND PAYER CONSOLIDATION.

(a) Annual Report on the Impact of Certain Medicare Regulations on Provider and Payer Consolidation; Public Comment on Provider and Payer Consolidation for Certain Proposed Rules.—

(1) Annual report.—Not later than December 30, 2026, and annually thereafter, the Secretary of Health and Human Services (in this section referred to as the “Secretary”) shall submit to Congress a report on the impact in the aggregate on provider and payer consolidation with respect to regulations for parts A, B, C, and D of title XVIII of the Social Security Act (42 U.S.C. 1395 et seq.) implemented in the calendar year immediately prior to such report. Such report shall include regulations that—

(A) implement a change to an applicable payment system, a rate schedule, or another payment system under part A, B, C, or D of such title; or

(B) result in a significant rule effecting provider or payer consolidation.

(2) Public comment on impact to provider and payer consolidation.—Beginning for 2025,
as part of any notice and comment rulemaking process that will result in a significant rule effecting provider or payer consolidation with respect to a proposed rule for parts A, B, C, and D of title XVIII of the Social Security Act (42 U.S.C. 1395j et seq.), the Secretary shall seek public comment on the projected impact of such proposed rule on provider and payer consolidation in the aggregate.

(3) DEFINITIONS.—In this section:

(A) PROVIDER AND PAYER CONSOLIDATION.—The term “provider and payer consolidation” includes the vertical or horizontal integration among providers of services (as defined in subsection (u) of section 1861 of the Social Security Act (42 U.S.C. 1395x)), suppliers (as defined in subsection (d) of such section), accountable care organizations under section 1899 of the Social Security Act (42 U.S.C. 1395jjx), Medicare Advantage organizations, PDP sponsors, pharmacy benefit managers, pharmacies, and integrated delivery systems.

(B) APPLICABLE PAYMENT SYSTEM.—The term “applicable payment system” includes—

(i) with respect to outpatient hospital services, the prospective payment system
for covered OPD services established under section 1833(t) of such Act (42 U.S.C. 1395(l)); and

(ii) with respect to physicians’ services, the physician fee schedules established under section 1848 of such Act (42 U.S.C. 1395w–4).

(b) CONSIDERATION OF EFFECTS ON PROVIDER AND PAYER CONSOLIDATION WITH RESPECT TO CMI MODELS.—

(1) IN GENERAL.—Section 1115A(b)(4)(A) of the Social Security Act (42 U.S.C. 1315a(b)(4)(A)) is amended—

(A) in clause (i), by striking at the end “and”;

(B) in clause (ii), by striking the period at the end and inserting “; and”; and

(C) by adding at the end the following new clause:

“(iii) the extent to which, and how, the model has effected and could effect provider and payer consolidation, which includes the vertical or horizontal integration among providers of services (as defined in subsection (u) of section 1861), suppliers
(as defined in subsection (d) of such section), and accountable care organizations under section 1899.”.

(2) **Effective Date.**—The amendments made by paragraph (1) shall apply with respect to models tested on or after January 1, 2025.

**SEC. 111. IMPLEMENTATION FUNDING.**

(a) **In General.**—For the purposes described in subsection (b), there are appropriated, out of amounts in the Treasury not otherwise appropriated, to the Secretary of Health and Human Services and the Secretary of the Treasury, $25,000,000 for fiscal year 2024, to remain available through fiscal year 2029.

(b) **Permitted Purposes.**—The purposes described in this subsection are the following purposes, insofar as such purposes are to carry out the provisions of, including the amendments made by, this title:

(1) Preparing, drafting, and issuing proposed and final regulations or interim regulations.

(2) Preparing, drafting, and issuing guidance and public information.

(3) Preparing, drafting, and publishing reports.

(4) Enforcement of such provisions.

(5) Reporting, collection, and analysis of data.
(6) Other administrative duties necessary for implementation of such provisions.

(c) TRANSPARENCY OF IMPLEMENTATION FUNDS.—

Each Secretary described in subsection (a) shall annually submit, no later than September 1st of each year, to the Committees on Energy and Commerce, on Ways and Means, on Education and Workforce, and on Appropriations of the House of Representatives and on the Committees on Health, Education, Labor, and Pensions and on Appropriations of the Senate a report on funds expended pursuant to funds appropriated under this section.

TITLE II—REDUCING HEALTH CARE COSTS FOR PATIENTS

SEC. 201. INCREASING TRANSPARENCY IN GENERIC DRUG APPLICATIONS.

(a) IN GENERAL.—Section 505(j)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(3)) is amended by adding at the end the following:

“(H)(i) Upon request (in controlled correspondence or an analogous process) by a person that has submitted or intends to submit an abbreviated application under this subsection for a drug that is required by regulation to contain one or more of the same inactive ingredients in the same concentrations as the listed drug referred to, or for which the Secretary determines there is a scientific jus-
171

tification for an approach that is in vitro in whole or in
part to be used to demonstrate bioequivalence for a drug
if such a drug contains one or more of the same inactive
ingredients in the same concentrations as the listed drug,
the Secretary shall inform the person whether such drug
is qualitatively and quantitatively the same as the listed
drug. The Secretary may also provide such information
to such a person on the Secretary’s own initiative during
the review of an abbreviated application under this sub-
section for such drug.

“(ii) Notwithstanding section 301(j), if the Secretary
determines that such drug is not qualitatively or quan-
titatively the same as the listed drug, the Secretary shall
identify and disclose to the person—

“(I) the ingredient or ingredients that cause
such drug not to be qualitatively or quantitatively
the same as the listed drug; and

“(II) for any ingredient for which there is an
identified quantitative deviation, the amount of such
deviation.

“(iii) If the Secretary determines that such drug is
qualitatively and quantitatively the same as the listed
drug, the Secretary shall not change or rescind such deter-
mination after the submission of an abbreviated applica-
tion for such drug under this subsection unless—
“(I) the formulation of the listed drug has been changed and the Secretary has determined that the prior listed drug formulation was withdrawn for reasons of safety or effectiveness; or

“(II) the Secretary makes a written determination that the prior determination must be changed because an error has been identified.

“(iv) If the Secretary makes a written determination described in clause (iii)(II), the Secretary shall provide notice and a copy of the written determination to the person making the request under clause (i).

“(v) The disclosures required by this subparagraph are disclosures authorized by law, including for purposes of section 1905 of title 18, United States Code.”.

(b) GUIDANCE.—

(1) IN GENERAL.—Not later than one year after the date of enactment of this Act, the Secretary of Health and Human Services shall issue draft guidance, or update guidance, describing how the Secretary will determine whether a drug is qualitatively and quantitatively the same as the listed drug (as such terms are used in section 505(j)(3)(H) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a)), including with respect to assessing pH adjusters.
(2) PROCESS.—In issuing guidance under this subsection, the Secretary of Health and Human Services shall—

(A) publish draft guidance;

(B) provide a period of at least 60 days for comment on the draft guidance; and

(C) after considering any comments received and not later than one year after the close of the comment period on the draft guidance, publish final guidance.

(c) APPLICABILITY.—Section 505(j)(3)(H) of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), applies beginning on the date of enactment of this Act, irrespective of the date on which the guidance required by subsection (b) is finalized.

SEC. 202. IMPROVING TRANSPARENCY AND PREVENTING THE USE OF ABUSIVE SPREAD PRICING AND RELATED PRACTICES IN MEDICAID.

(a) PHARMACY PRICE REIMBURSEMENT REQUIREMENTS.—

(1) IN GENERAL.—Section 1927(e) of the Social Security Act (42 U.S.C. 1396r–8(e)) is amended by adding at the end the following:

“(6) PHARMACY PRICE REIMBURSEMENT REQUIRED.—
“(A) In general.—A contract between the State and a pharmacy benefit manager (in this paragraph referred to as a ‘PBM’), or a contract between the State and a designated entity (as defined in subparagraph (C)) that includes provisions making the designated entity responsible for the administration of medical assistance consisting of covered outpatient drugs for individuals enrolled with the designated entity, shall require that payment for such drugs and related administrative services (as applicable), including payments made by a PBM on behalf of the State or designated entity, is based on pharmacy price reimbursement model under which—

“(i) any payment made by the designated entity or the PBM (as applicable) for such a drug—

“(I) is limited to—

“(aa) ingredient cost; and

“(bb) a professional dispensing fee that is not less than the professional dispensing fee that the State plan or waiver
would pay if the plan or waiver was making the payment directly;

“(II) is passed through in its entirety by the designated entity or PBM to the pharmacy or provider that dispenses the drug and is not retroactively denied or reduced except as the result of an audit performed pursuant to a contract between such designated entity or PBM and such pharmacy or provider, or as otherwise permitted or required by law (including in response to instances of fraud, waste, or abuse); and

“(III) is made in a manner that is consistent with sections 447.502, 447.512, 447.514, and 447.518 of title 42, Code of Federal Regulations (or any successor regulation) as if such requirements applied directly to the designated entity or the PBM, except that any payment by the designated entity or the PBM for the ingredient cost of such a drug purchased by a covered entity (as defined
in subsection (a)(5)(B)) may exceed
the actual acquisition cost (as defined
in section 447.502 of title 42, Code of
Federal Regulations (or any successor
regulation)) for such drug if—

“(aa) such drug was subject
to an agreement under section
340B of the Public Health Serv-
ice Act;

“(bb) such payment for such
cost of such drug does not exceed
the maximum payment that
would have been made by the
designated entity or the PBM for
the ingredient cost of such drug
had such drug not been pur-
chased by such a covered entity;
and

“(cc) such covered entity re-
ports to the Secretary, on an an-
nual basis (in a form and manner
specified by the Secretary) and
with respect to payments for
such costs of such drugs so pur-
chased by such covered entity
that are in excess of the actual
acquisition costs for such drugs,
the aggregate amount of such ex-
cess;

“(ii) payment to the designated entity
or the PBM (as applicable) for administra-
tive services performed by the designated
entity or PBM is limited to an administra-
tive fee that reflects the fair market value
of providing such services;

“(iii) the designated entity or the
PBM (as applicable) makes available to
the State, and the Secretary upon request,
all costs and payments related to covered
outpatient drugs and accompanying admin-
istrative services incurred, received, or
made by the designated entity or the PBM,
including ingredient costs, professional dis-
pensing fees, administrative fees, post-sale
and post-invoice fees, discounts, or related
adjustments such as direct and indirect re-
muneration fees, and any and all other re-
muneration; and

“(iv) any form of spread pricing
whereby any amount charged or claimed by
the designated entity or the PBM (as applicable) is in excess of the amount paid to the pharmacies by the designated entity or the PBM, including any post-sale or post-invoice fees, discounts, or related adjustments such as direct and indirect remuneration fees or assessments (after allowing for a fair market administrative fee as described in clause (ii)), is not allowable for purposes of claiming Federal matching payments under this title.

“(B) MAKING CERTAIN INFORMATION AVAILABLE.—The Secretary shall publish, not less frequently than on an annual basis, information received by the Secretary pursuant to subparagraph (A)(i)(III)(cc). Such information shall be so published in an electronic and searchable format, such as through the 340B Office of Pharmacy Affairs Information System (or a successor system).

“(C) DEFINITIONS.—In this paragraph:

“(i) DESIGNATED ENTITY.—The term ‘designated entity’ means a managed care entity or other specified entity.
“(ii) MANAGED CARE ENTITY; OTHER SPECIFIED ENTITY.—The terms ‘managed care entity’ and ‘other specified entity’ have the meaning given such terms in section 1903(m)(9)(D).”.

(2) CONFORMING AMENDMENTS.—Section 1903(m)(2)(A) of such Act (42 U.S.C. 1396b(m)(2)(A)) is amended—

(A) in clause (i), by inserting before the semicolon at the end the following: “(or, in the case of a contract described in section 1927(e)(6), is an other specified entity (as defined in paragraph (9)(D))”;

(B) in clause (xiii)—

(i) by striking “and (III)” and inserting “(III)”;

(ii) by inserting before the period at the end the following: “, and (IV) the pharmacy benefit provided by the entity (or pharmacy benefit manager on behalf of the entity under a contract), the other specified entity (as defined in paragraph (9)(D)) (or pharmacy benefit manager on behalf of the other specified entity under a contract), or by another arrangement be-
tween the entity or other specified entity and the pharmacy benefit manager, shall comply with the requirements of section 1927(e)(6)”; and

(iii) by moving the margin 2 ems to the left.

(3) EFFECTIVE DATE.—The amendments made by this subsection apply to contracts between States and pharmacy benefit managers and designated entities (as defined in section 1927(e)(6) of the Social Security Act, as added by paragraph (1)) that have an effective date beginning on or after the date that is 18 months after the date of enactment of this Act.

(b) ENSURING ACCURATE PAYMENTS TO PHARMACIES UNDER MEDICAID.—

(1) IN GENERAL.—Section 1927(f) of the Social Security Act (42 U.S.C. 1396r–8(f)) is amended—

(A) by striking “and” after the semicolon at the end of paragraph (1)(A)(i) and all that precedes it through “(1)” and inserting the following:

“(1) DETERMINING PHARMACY ACTUAL ACQUISITION COSTS.—The Secretary shall conduct a survey of retail community pharmacy drug prices to de-
termine the national average drug acquisition cost as
follows:

“(A) USE OF VENDOR.—The Secretary
may contract services for—

“(i) with respect to retail community
pharmacies, the determination of retail
survey prices of the national average drug
acquisition cost for covered outpatient
drugs based on a monthly survey of such
pharmacies; and”;

(B) by adding at the end of paragraph (1)
the following:

“(F) SURVEY REPORTING.—A State shall
require that any retail community pharmacy in
the State that receives any payment, reimburse-
ment, administrative fee, discount, or rebate re-
lated to the dispensing of covered outpatient
drugs to individuals receiving benefits under
this title, regardless of whether such payment,
reimbursement, administrative fee, discount, or
rebate is received from the State or a des-
ignated entity (as defined in subsection
(e)(6)(C)) directly or from a pharmacy benefit
manager that has a contract with the State or
a designated entity, shall respond to surveys of retail prices conducted under this subsection.

“(G) Survey information.—Information on national drug acquisition prices obtained under this paragraph shall be made publicly available in a timely manner following the collection of such information and shall include at least the following:

“(i) The monthly response rate to the survey including a list of pharmacies not in compliance with subparagraph (F).

“(ii) The sampling frame and number of pharmacies sampled monthly.

“(iii) Information on price concessions to the pharmacy, including discounts, rebates, and other price concessions, to the extent that such information may be publicly released and is available during the survey period.

“(H) Report on specialty pharmacies.—Not later than 1 year after the date that this subparagraph takes effect, the Secretary shall submit to Congress a report examining specialty drug coverage and reimbursement under this title, including—
“(i) a description of how State Medicaid programs define specialty drugs and specialty pharmacies;

“(ii) the amount State Medicaid programs pay for specialty drugs;

“(iii) how States and designated entities (as defined in subsection (e)(6)(C)) determine payment for specialty drugs;

“(iv) the settings in which specialty drugs are dispensed to individuals receiving benefits under this title (such as retail community pharmacies or specialty pharmacies);

“(v) the extent to which specialty drugs (as defined by the respective States) are captured in the national average drug acquisition cost survey (or through another process);

“(vi) examples of specialty drug dispensing fees to support the services associated with dispensing such specialty drugs; and

“(vii) recommendations as to whether specialty pharmacies should be included in the survey of retail prices to ensure na-
tional average drug acquisition costs capture drugs sold at specialty pharmacies, and how such specialty pharmacies should be defined.

“(I) ENFORCEMENT.—At the discretion of the Secretary, the Secretary (acting through the Inspector General and in collaboration with the Administrator of the Centers for Medicare & Medicaid Services) may enforce non-compliance with this paragraph by a pharmacy through the establishment of penalties until compliance with this paragraph has been completed.”; and

(C) in paragraph (2)—

(i) in subparagraph (A), by inserting “(including payment rates under managed care organization as defined in section 1932(a)(1)(B)(i) and PIHPs and PAHPs as defined in section 1903(m)(9)(D)(iii)(I) and (II), respectively)” after “under this title”; and

(ii) in subparagraph (B), by inserting “, and the basis for such dispensing fees” before the semicolon at the end.

(2) EFFECTIVE DATE.—The amendments made by this subsection shall take effect on the first day
of the first quarter that begins on or after the date
that is 18 months after the date of enactment of
this Act.

4 SEC. 203. PARITY IN MEDICARE PAYMENTS FOR HOSPITAL
OUTPATIENT DEPARTMENT SERVICES FUR-
NISHED OFF-CAMPUS.

(a) IN GENERAL.—Section 1833(t)(16) of the Social
Security Act (42 U.S.C. 1395l(t)(16)) is amended by add-
ing at the end the following new subparagraph:

“(H) Parity in fee schedule amount
for certain services furnished by an
off-campus outpatient department of a
provider.—

“(i) In general.—Subject to clause
(iii), in the case of specified OPD services
(as defined in clause (v)) that are fur-
ishied during 2025 or a subsequent year
by an off-campus outpatient department of
a provider (as defined in clause (iv)) (or,
in the case of an off-campus outpatient de-
partment of a provider that is a hospital
described in section 1886(d)(1)(B)(v), or is
located in a rural area or a health profes-
sional shortage area, such services that are
furnished during 2026 or a subsequent
year), there shall be substituted for the amount otherwise determined under this subsection for such service and year an amount equal to the payment amount that would have been payable under the applicable payment system under this part (other than under this subsection) had such services been furnished by such a department subject to such payment system pursuant to paragraph (21)(C).

“(ii) NOT BUDGET NEUTRAL IMPLEMENTATION.—In making any budget neutrality adjustments under this subsection for 2025 or a subsequent year, the Secretary shall not take into account the reduced expenditures that result from the application of this subparagraph.

“(iii) TRANSITION.—The Secretary shall provide for a 4-year phase-in of the application of clause (i), with clause (i) being fully applicable for specified OPD services beginning with 2028 (or in the case of an off-campus outpatient department of a provider that is a hospital described in section 1886(d)(1)(B)(v), or is
located in a rural area or a health professional shortage area, beginning with 2029).

“(iv) OFF-CAMPUS DEPARTMENT OF A PROVIDER.—For purposes of this subparagraph, the term ‘off-campus outpatient department of a provider’ means a department of a provider (as defined in section 413.65(a)(2) of title 42, Code of Federal Regulations) that is not located—

“(I) on the campus (as such term is defined in such section) of such provider; or

“(II) within the distance (described in such definition of campus) from a remote location of a hospital facility (as defined in such section).

“(v) OTHER DEFINITIONS.—For purposes of this subparagraph:

“(I) DESIGNATED AMBULATORY PAYMENT CLASSIFICATION GROUP.—

The term ‘designated ambulatory payment classification group’ means an ambulatory payment classification group for drug administration services.
“(II) Health professional shortage area.—The term ‘health professional shortage area’ has the meaning given such term in section 332(a)(1)(A) of the Public Health Service Act.

“(III) Rural area.—The term ‘rural area’ has the meaning given such term in section 1886(d)(2)(D).

“(IV) Specified OPD services.—The term ‘specified OPD services’ means covered OPD services assigned to a designated ambulatory payment classification group.”.

(b) Implementation.—Section 1833(t)(12) of the Social Security Act (42 U.S.C. 1395l(t)(12)) is amended—

(1) in subparagraph (D), by striking “and” at the end;

(2) in subparagraph (E), by striking the period at the end and inserting “; and”; and

(3) by adding at the end the following new subparagraph:

“(F) the determination of any payment amount under paragraph (16)(H), including the
transition under clause (iii) of such paragraph.”.

SEC. 204. REQUIRING A SEPARATE IDENTIFICATION NUMBER AND AN ATTESTATION FOR EACH OFF-CAMPUS OUTPATIENT DEPARTMENT OF A PROVIDER.

(a) IN GENERAL.—Section 1833(t) of the Social Security Act (42 U.S.C. 1395l(t)) is amended by adding at the end the following new paragraph:

“(23) USE OF UNIQUE HEALTH IDENTIFIERS; ATTESTATION.—

“(A) IN GENERAL.—No payment may be made under this subsection (or under an applicable payment system pursuant to paragraph (21)) for items and services furnished on or after January 1, 2026, by an off-campus outpatient department of a provider (as defined in subparagraph (C)) unless—

“(i) such department has obtained, and such items and services are billed under, a standard unique health identifier for health care providers (as described in section 1173(b)) that is separate from such identifier for such provider; and
“(ii) such provider has submitted to the Secretary, during the 2-year period ending on the date such items and services are so furnished, an attestation that such department is compliant with the requirements described in section 413.65 of title 42, Code of Federal Regulations (or a successor regulation).

“(B) PROCESS FOR SUBMISSION AND REVIEW.—Not later than 1 year after the date of enactment of this paragraph, the Secretary shall, through notice and comment rulemaking, establish a process for each provider with an off-campus outpatient department of a provider to submit an attestation pursuant to subparagraph (A)(ii), and for the Secretary to review each such attestation and determine, through site visits, remote audits, or other means (as determined appropriate by the Secretary), whether such department is compliant with the requirements described in such subparagraph.

“(C) OFF-CAMPUS OUTPATIENT DEPARTMENT OF A PROVIDER DEFINED.—For purposes of this paragraph, the term ‘off-campus outpatient department of a provider’ means a de-
partment of a provider (as defined in section 413.65 of title 42, Code of Federal Regulations, or any successor regulation) that is not located—

“(i) on the campus (as defined in such section) of such provider; or

“(ii) within the distance (described in such definition of campus) from a remote location of a hospital facility (as defined in such section).”.

(b) HHS OIG Analysis.—Not later than January 1, 2030, the Inspector General of the Department of Health and Human Services shall submit to Congress—

(1) an analysis of the process established by the Secretary of Health and Human Services to conduct the reviews and determinations described in section 1833(t)(23)(B) of the Social Security Act, as added by subsection (a) of this section; and

(2) recommendations based on such analysis, as the Inspector General determines appropriate.
TITLE III—SUPPORTING PATIENTS, HEALTH CARE WORKERS, COMMUNITY HEALTH CENTERS, AND HOSPITALS

SEC. 301. EXTENSION FOR COMMUNITY HEALTH CENTERS, THE NATIONAL HEALTH SERVICE CORPS, AND TEACHING HEALTH CENTERS THAT OPERATE GME PROGRAMS.

(a) Teaching Health Centers that Operate Graduate Medical Education Programs.—

(1) Addition to capped amounts for fiscal years 2024 and 2025.—Paragraph (2) of section 340H(b) of the Public Health Service Act (42 U.S.C. 256h(b)) is amended by adding at the end the following:

“(C) Addition.—Notwithstanding any provision of this section, for each of fiscal years 2024 and 2025, the Secretary may use any amounts made available in any fiscal year to carry out this section (including amounts recouped under subsection (f)) to make payments described in paragraphs (1)(A) and (1)(B), in addition to the total amount of funds appropriated under subsection (g).”.
(2) RECONCILIATION.—Section 340H(f) of the Public Health Service Act (42 U.S.C. 256h(f)) is amended—

(A) by striking “The Secretary shall deter-
mine” and inserting the following:

“(1) DETERMINATION.—The Secretary shall de-
termine”; and

(B) by adding at the end the following:

“(2) ANNUAL REPORT TO CONGRESS.—For each fiscal year, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a re-
port specifying—

“(A) the total amount of funds recouped under paragraph (1);

“(B) the rationale for the funds being re-
couped; and

“(C) in the case of the reports for each of fiscal years 2024 and 2025, the total amount of funds recouped under paragraph (1) that were used pursuant to subsection (b)(2)(C) to adjust total payment amounts above the total amounts appropriated under subsection (g).”).
(3) FUNDING.—Section 340H(g) of the Public Health Service Act (42 U.S.C. 256h(g)) is amended—

(A) by amending paragraph (1) to read as follows:

“(1) IN GENERAL.—To carry out this section, there are appropriated such sums as may be necessary, not to exceed—

“(A) $230,000,000, for the period of fiscal years 2011 through 2015;

“(B) $60,000,000 for each of fiscal years 2016 and 2017;

“(C) $126,500,000 for each of fiscal years 2018 through 2023;

“(D) $175,000,000 for each of fiscal years 2024 and 2025;

“(E) $225,000,000 for each of fiscal years 2026 and 2027; and

“(F) $300,000,000 for each of fiscal years 2028, 2029, and 2030.”; and

(B) by adding at the end the following:

“(3) AVAILABILITY.—The amounts made available under paragraph (1) shall remain available until expended.”.
(b) Extension for Community Health Centers.—Section 10503(b)(1)(F) of the Patient Protection and Affordable Care Act (42 U.S.C. 254b–2(b)(1)(F)) is amended—

(1) by striking “and” before “$4,000,000,000” and inserting a comma; and

(2) by inserting “, $4,400,000,000 for each of fiscal years 2024 and 2025, and $1,109,000,000 for the period beginning October 1, 2025, and ending December 31, 2025” before the semicolon.

(c) Extension for the National Health Service Corps.—Section 10503(b)(2) of the Patient Protection and Affordable Care Act (42 U.S.C. 254b–2(b)(2)) is amended—

(1) in subparagraph (G), by striking “and” at the end;

(2) in subparagraph (H), by striking the period at the end and inserting “; and”; and

(3) by adding at the end the following:

“(I) $350,000,000 for each of fiscal years 2024 and 2025, and $88,219,178 for the period beginning October 1, 2025, and ending December 31, 2025.”.

(d) Government Accountability Office Report.—
(1) IN GENERAL.—Not later than one year after the date of enactment of this Act, the Comptroller General of the United States shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report assessing the effectiveness of the National Health Service Corps at attracting health care professionals to HPSAs, including by—

(A) assessing the metrics used by the Health Resources and Services Administration in evaluating the program;

(B) comparing the retention rates of NHSC participants in the HPSAs where they completed their period of obligated service to the retention rate of non-NHSC participants in the corresponding HPSAs;

(C) comparing the retention rates of NHSC participants in the HPSAs where they completed their period of obligated service to the retention rates of NHSC participants in HPSAs other than those where they completed their period of obligated service;

(D) identifying factors that influence a NHSC participant’s decision to practice in a
HPSA other than the HPSA where they completed their period of obligated service;

(E) identifying factors other than participation in the National Health Service Corps Scholarship and Loan Repayment Programs that attract health care professionals to a HPSA;

(F) assessing the impact the National Health Service Corps has on wages for health care professionals in a HPSA; and

(G) comparing the distribution of NHSC participants across HPSAs, including a comparison of rural versus non-rural HPSAs.

(2) DEFINITION.—In this section:

(A) The term “HPSA” means a health professional shortage area designated under section 332 of the Public Health Service Act (42 U.S.C. 254e).

(B) The term “NHSC participant” means a National Health Service Corps member participating in the National Health Service Corps Scholarship or Loan Repayment Program.

(e) APPLICATION OF PROVISIONS.—Amounts appropriated pursuant to the amendments made by this section shall be subject to the requirements contained in Public
Law 117–328 for funds for programs authorized under sections 330 through 340 of the Public Health Service Act.

(f) CONFORMING AMENDMENT.—Paragraph (4) of section 3014(h) of title 18, United States Code, is amended by striking “and section 301(d) of division BB of the Consolidated Appropriations Act, 2021.” and inserting “section 301(d) of division BB of the Consolidated Appropriations Act, 2021, and section 301(e) of the Lower Costs, More Transparency Act.”.

SEC. 302. EXTENSION OF SPECIAL DIABETES PROGRAMS.

(a) EXTENSION OF SPECIAL DIABETES PROGRAMS FOR TYPE I DIABETES.—Section 330B(b)(2) of the Public Health Service Act (42 U.S.C. 254c–2(b)(2)) is amended—

(1) in subparagraph (C), by striking “and” at the end;

(2) in subparagraph (D), by striking the period at the end and inserting a semicolon; and

(3) by adding at the end the following:

“(E) $170,000,000 for each of fiscal years 2024 and 2025, to remain available until expended; and
“(F) $42,849,315 for the period beginning October 1, 2025, and ending December 31, 2025, to remain available until expended.”.

(b) Extending Funding for Special Diabetes Programs for Indians.—Section 330C(c)(2) of the Public Health Service Act (42 U.S.C. 254c–3(c)(2)) is amended—

(1) in subparagraph (C), by striking “and” at the end;

(2) in subparagraph (D), by striking the period at the end and inserting a semicolon; and

(3) by adding at the end the following:

“(E) $170,000,000 for each of fiscal years 2024 and 2025, to remain available until expended; and

“(F) $42,849,315 for the period beginning October 1, 2025, and ending December 31, 2025, to remain available until expended.”.

SEC. 303. DELAYING CERTAIN DISPROPORTIONATE SHARE HOSPITAL PAYMENT REDUCTIONS UNDER THE MEDICAID PROGRAM.

Section 1923(f)(7)(A) of the Social Security Act (42 U.S.C.1396r–4(f)(7)(A)) is amended—
(1) in clause (i), in the matter preceding sub-
clause (I), by striking “2024” and inserting “2026”; 
and
(2) in clause (ii), by striking “2024” and in-
serting “2026”.

SEC. 304. MEDICAID IMPROVEMENT FUND.

Section 1941(b)(3)(A) of the Social Security Act (42 
U.S.C. 1396w–1(b)(3)(A)) is amended by striking 
“$7,000,000,000” and inserting “$0”.

TITLE IV—INCREASING ACCESS 
TO QUALITY HEALTH DATA 
AND LOWERING HIDDEN 
FEES

SEC. 401. INCREASING PLAN FIDUCIARIES’ ACCESS TO 
HEALTH DATA.

(a) Plan Fiduciary Access to Information.—

(1) In general.—Paragraph (2) of section 
408(b) of the Employee Retirement Income Security 
Act of 1974 (29 U.S.C. 1108(b)) is amended by 
adding at the end the following new subparagraph:

“(C) No contract or arrangement for services 
between a group health plan and any other entity, 
including a health care provider (including a health 
care facility), network or association of providers, 
service provider offering access to a network of pro-
viders, third-party administrator, or pharmacy benefit manager, is reasonable within the meaning of this paragraph unless such contract or arrangement—

“(i) allows the responsible plan fiduciary to audit or review all de-identified claims and encounter information or data described in section 724(a)(1)(B) to—

“(I) ensure that such entity complies with the terms of the plan and any applicable law; and

“(II) determine the reasonableness of compensation received by such entity; and

“(ii) does not—

“(I) unreasonably limit the number of audits permitted during a given period of time;

“(II) limit the number of de-identified claims and encounter information or data that the responsible plan fiduciary may access during an audit;

“(III) limit the disclosure of pricing terms for value-based payment arrangements or capitated payment arrangements, including—
“(aa) payment calculations and formulas;

“(bb) quality measures;

“(cc) contract terms;

“(dd) payment amounts;

“(ee) measurement periods for all incentives; and

“(ff) other payment methodologies used by an entity, including a health care provider (including a health care facility), network or association of providers, service provider offering access to a network of providers, third-party administrator, or pharmacy benefit manager;

“(IV) limit the disclosure of overpayments and overpayment recovery terms;

“(V) limit the right of the responsible plan fiduciary to select an auditor;

“(VI) otherwise limit or unduly delay by greater than 60 calendar days after the date of request the responsible plan fiduciary from auditing all de-identified claims and encounter information or data; or
“(VII) permit the entity to charge a fee beyond the reasonable direct costs to provide the required information and otherwise comply and assist with an audit request.

“(D) PRIVACY REQUIREMENTS.—Covered service providers shall provide information under this subparagraph in a manner consistent with the privacy, security, and breach notification regulations promulgated under section 13402(a) of the Health Information Technology for Clinical Health Act, and shall restrict the use and disclosure of such information according to such privacy regulations.

“(E) DISCLOSURE AND REDISCLOSURE.—

“(i) LIMITATION TO BUSINESS ASSOCIATES.—A responsible plan fiduciary receiving a report under this subparagraph may disclose such information only to the entity from which the report was received, the group health plan for which the report pertains, or to that entity’s business associates as defined in section 160.103 of title 45, Code of Federal Regulations (or successor regulations) or as permitted by the
HIPAA Privacy Rule (45 CFR parts 160 and 164, subparts A and E).

“(ii) CLARIFICATION REGARDING PUBLIC DISCLOSURE OF INFORMATION.—Nothing in this section shall prevent a group health plan or health insurance issuer offering group health insurance coverage, or a covered service provider, from placing reasonable restrictions on the public disclosure of the information contained in a report described in this subparagraph, except that such plan, issuer, or entity may not restrict disclosure of such report to the Department of Labor.”.

(2) CIVIL ENFORCEMENT.—

(A) IN GENERAL.—Subsection (e) of section 502 of such Act (29 U.S.C. 1132) is amended by adding at the end the following new paragraph:

“(13) In the case of an agreement between a group health plan and a health care provider (including a health care facility), network or association of providers, service provider offering access to a network of providers, third-party administrator, or pharmacy benefit manager, that violates the provisions of section 724, the Secretary may
assess a civil penalty against such provider, network or association, service provider offering access to a network of providers, third-party administrator, pharmacy benefit manager, or other service provider in the amount of $10,000 for each day during which such violation continues. Such penalty shall be in addition to other penalties as may be prescribed by law.”.

(B) CONFORMING AMENDMENT.—Paragraph (6) of section 502(a) of such Act is amended by striking “or (9)” and inserting “(9), or (13)”.

(3) EXISTING PROVISIONS VOID.—Section 410 of such Act is amended by adding at the end the following new subsection:

“(c) Any provision in an agreement or instrument shall be void as against public policy if such provision—

“(1) unduly delays or limits a plan fiduciary from accessing the de-identified claims and encounter information or data described in section 724(a)(1)(B); or

“(2) violates the requirements of section 408(b)(2)(C).”.

(4) TECHNICAL AMENDMENT.—Clause (i) of section 408(b)(2)(B) of such Act is amended by
striking “this clause” and inserting “this paragraph”.

(b) UPDATED ATTESTATION FOR PRICE AND QUALITY INFORMATION.—Section 724(a)(3) of the Employee Retirement Income Security Act (29 U.S.C. 1185m(a)(3)) is amended to read as follows:

“(3) ATTESTATION.—

“(A) IN GENERAL.—Subject to subparagraph (C), the plan fiduciary of a group health plan or health insurance issuer offering group health insurance coverage shall annually submit to the Secretary an attestation that such plan or issuer of such coverage is in compliance with the requirements of this subsection. Such attestation shall also include a statement verifying that—

“(i) the information or data described under subparagraphs (A) and (B) of paragraph (1) is available upon request and provided to the plan fiduciary, the plan administrator, or the issuer in a timely manner; and

“(ii) there are no terms in the agreement under such paragraph (1) that directly or indirectly restrict or unduly delay
a plan fiduciary, the plan administrator, or
the issuer from auditing, reviewing, or oth-
erwise accessing such information, except
as permitted under section 408(b)(2)(C).

“(B) LIMITATION ON SUBMISSION.—Sub-
ject to clause (ii), a group health plan or issuer
offering group health insurance coverage may
not enter into an agreement with a third-party
administrator or other service provider to sub-
mit the attestation required under subpar-
agraph (A).

“(C) EXCEPTION.—In the case of a group
health plan or issuer offering group health in-
surance coverage that is unable to obtain the
information or data needed to submit the attes-
tation required under subparagraph (A), such
plan or issuer may submit a written statement
in lieu of such attestation that includes—

“(i) an explanation of why such plan
or issuer was unsuccessful in obtaining
such information or data, including wheth-
er such plan or issuer was limited or pre-
vented from auditing, reviewing, or other-
wise accessing such information or data;
“(ii) a description of the efforts made by the plan fiduciary to remove any gag clause provisions from the agreement under paragraph (1); and

“(iii) a description of any response by the third-party administrator or other service provider with respect to efforts to comply with the attestation requirement under subparagraph (A).”.

(c) REPORT ON PLAN ASSETS.—Not later than 1 year after the date of enactment of this Act, the Secretary of Labor shall submit to the Committee on Education and the Workforce of the House of Representatives a report on the status of de-identified claims and encounter information or data described in section 724(a)(1)(B) of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1185m), including information on the following:

(1) Whether changes to regulations or guidance would permit such information or data to be deemed a group health plan asset (as defined under section 3(42) of such Act).

(2) Whether restrictions on the ability of a plan fiduciary to access such information or data violates a requirement of current law.
(3) The existing regulatory authority of the Secretary to clarify whether such information or data is the property of a group health plan, rather than a service provider.

(4) Legislative actions that may be taken to establish that such information or data related to a plan belongs to a group health plan and is handled in the best interests of plan participants and beneficiaries.

(d) EFFECTIVE DATE.—The amendments made by subsections (a) and (b) shall apply with respect to a plan beginning with the first plan year that begins on or after the date that is 1 year after the date of enactment of this Act.

SEC. 402. HIDDEN FEES DISCLOSURE REQUIREMENTS.

(a) CLARIFICATION OF THE APPLICATION OF FEE DISCLOSURE REQUIREMENTS TO COVERED SERVICE PROVIDERS.—


(A) in subitem (AA) by striking “Brokerage services,” and inserting “Services (including brokerage services),”;

and
(B) in subitem (BB)—

(i) by striking “Consulting,” and inser-
ting “Other services,”; and

(ii) by inserting “any of the fol-
lowing;” before “plan design”.

(2) DISCLOSURES.—Clause (iii)(III) of section 408(b)(2)(B) of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1108(b)(2)(B)) is amended by striking “, either in the aggregate or by service,” and inserting “by service”.

(b) STRENGTHENING DISCLOSURE REQUIREMENTS WITH RESPECT TO PHARMACY BENEFIT MANAGERS AND THIRD PARTY ADMINISTRATORS FOR GROUP HEALTH PLANS.—

(1) CERTAIN ARRANGEMENTS FOR PBM SERVICES CONSIDERED AS INDIRECT.—

(A) IN GENERAL.—Clause (i) of section 408(b)(2)(B) of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1108(b)(2)(B)) is amended—

(i) by striking “requirements of this clause” and inserting “requirements of this subparagraph”; and

(ii) by adding at the end the fol-
lowing: “For purposes of applying section
406(a)(1)(C) with respect to a transaction described under this subparagraph, a contract or arrangement for services between a covered plan and a health insurance issuer providing health insurance coverage in connection with the covered plan in which the health insurance issuer contracts, in connection with such plan, with a service provider for pharmacy benefit management services shall be considered to constitute an indirect furnishing of goods, services, or facilities between the plan and the service provider acting as the party in interest.”.

(B) HEALTH INSURANCE ISSUER AND HEALTH INSURANCE COVERAGE DEFINED.—Clause (ii)(I)(aa) of section 408(b)(2)(B) of such Act ((29 U.S.C. 1108(b)(2)(B)) is amended by inserting before the period at the end “and the terms ‘health insurance coverage’ and ‘health insurance issuer’ have the meanings given such terms in section 733(b)”.

(C) TECHNICAL AMENDMENT.—Clause (ii)(I)(aa) of section 408(b)(2)(B) of the Employee Retirement Income Security Act of 1974
((29 U.S.C. 1108(b)(2)(B)) is further amended by inserting “in” after “defined”.

(2) Specific disclosure requirements with respect to pharmacy benefit management services.—

(A) In general.—Clause (iii) of section 408(b)(2)(B) of such Act (29 U.S.C. 1108(b)(2)(B)) is amended by adding at the end the following:

“(VII) With respect to a contract or arrangement with the covered plan in connection with the provision of pharmacy benefit management services, as part of the description required under subclauses (III) and (IV)—

“(aa) all compensation described in clause (ii)(I)(dd)(AA), including fees, rebates, alternative discounts, co-payment offsets, and other remuneration expected to be received by the covered service provider, an affiliate, or a subcontractor from a pharmaceutical manufacturer, distributor, rebate aggregator, accumulator, and maximizer, group purchasing organization, or any other third party;
“(bb) the amount and form of any rebates, discounts, or price concessions, including the amount expected to be passed through to the plan sponsor or the participants and beneficiaries under the covered plan;

“(cc) all compensation expected to be received by the covered service provider, an affiliate, or a subcontractor as a result of paying a lower amount for the drug than the amount charged as a copayment, coinsurance amount, or deductible;

“(dd) all compensation expected to be received by the covered service provider, an affiliate, or a subcontractor as a result of paying pharmacies less than what is charged the health plan, plan sponsor, or participants and beneficiaries under the covered plan; and

“(ee) all compensation expected to be received by the covered service provider, an affiliate, or a subcontractor from drug manufacturers and any other third party in exchange for—
“(AA) administering, invoicing, allocating, or collecting rebates related to the covered plan;

“(BB) providing business services and activities, including providing access to drug utilization data;

“(CC) keeping a percentage of the list price of a drug; or

“(DD) any other reason related to the role of a covered service provider as a conduit between the drug manufacturers or any other third party and the covered plan.”.

(B) ANNUAL DISCLOSURE.—Clause (v) of section 408(b)(2)(B) of such Act (29 U.S.C. 1108(b)(2)(B)) is amended by adding at the end the following:

“(III) A covered service provider, with respect to a contract or arrangement with the covered plan in connection with providing pharmacy benefit management services, shall disclose, on an annual basis not later than 60 days after the beginning of the current plan year, to a responsible plan fiduciary, in writing, the fol-
lowing with respect to the twelve months pre-
ceeding the current plan year:

“(aa) All direct compensation de-
scribed in subclause (III) of clause (iii)
and indirect compensation described in
subclause (IV) of clause (iii) received by
the covered service provider (including
such compensation described in subclause
(VII) of clause (iii)).

“(bb) For each drug covered under
the covered plan, the amount by which the
price for the drug paid by the plan exceeds
the amount paid to pharmacies by the cov-
ered service provider.

“(cc) The total gross spending by the
covered plan on drugs (excluding rebates,
discounts, or other price concessions).

“(dd) The total net spending by the
covered plan on drugs.

“(ee) The total gross spending at all
pharmacies wholly or partially owned by
the covered service provider or any entity
affiliated with the covered service provider,
including mail-order, specialty and retail
pharmacies, with a breakdown by individual pharmacy location.

“(ff) The aggregate amount of clawback from such pharmacies, including mail-order, specialty, and retail pharmacies.

“(AA) Categorical explanations (grouped by the reason for clawback, such as contractual true-up provisions, overpayments, or non-covered medication dispensed, and including information on the amount in each category that was passed through to the covered plan and to participants and beneficiaries of the covered plan); or

“(BB) Individual explanations for such clawbacks.

“(gg) Total aggregate amounts of fees collected by the covered service provider, an affiliate, or a subcontractor in connection with the provision of pharmacy benefit management services to the covered plan.

“(hh) Any other information specified by the Secretary through regulations or
guidance that may be necessary for a responsible plan fiduciary to consider the merits of the contract or arrangement with the covered service provider and any conflicts of interest that may exist.”.

(C) Pharmacy Benefit Management Services Defined.—Clause (ii)(I) of section 408(b)(2)(B) of such Act (29 U.S.C. 1108(b)(2)(B)) is amended by adding at the end the following:

“(gg) The term ‘pharmacy benefit management services’ includes any services provided by a covered service provider to a covered plan with respect to the administration of prescription drug benefits under the covered plan, including—

“(AA) the processing and payment of claims;

“(BB) design of pharmacy networks;

“(CC) negotiation, aggregation, and distribution of rebates, discounts, and other price concessions;

“(DD) formulary design and maintenance;
“(EE) operation of pharmacies
(whether retail, mail order, specialty
drug, or otherwise);
“(FF) recordkeeping;
“(GG) utilization review;
“(HH) adjudication of claims;
and
“(II) any other services specified
by the Secretary through guidance or
rulemaking.”.

(D) C L A W B A C K D E F I N E D .—Clause (ii)(I)
of section 408(b)(2)(B) of such Act (29 U.S.C.
1108(b)(2)(B)), as amended by subparagraph
(C), is amended by adding at the end the fol-
lowing:

“(hh) The term ‘clawback’ means
amounts collected by a provider of phar-
my benefit management services from a
pharmacy for copayments collected from a
participant or beneficiary in excess of the
contracted rate.”.

(3) S P E C I F I C D I S C O L S U R E R E Q U I R E M E N T S
W I T H R E S P E C T T O T H I R D P A R T Y A D M I N I S T R A T I O N
S E R V I C E S F O R G R O U P H E A L T H P L A N S . —
(A) IN GENERAL.—Clause (iii) of section 408(b)(2)(B) of such Act (29 U.S.C. 1108(b)(2)(B)), as amended by paragraph (2)(A), is amended by adding at the end the following:

“(VIII) With respect to a contract or arrangement with the covered plan in connection with the provision of third party administration services for group health plans, as part of the description required under subclauses (III) and (IV)—

“(aa) the amount and form of any rebates, discounts, savings fees, refunds, or amounts received from providers and facilities, including the amounts that will be retained by the covered service provider as a fee;

“(bb) the amount and form of fees expected to be received from other service providers in relation to the covered plan, including the amounts that will be retained by the covered service provider as a fee; and

“(cc) the amount and form of expected recoveries by the covered service provider
provider, including the amounts that will
be retained by the covered service provider
as a fee (disaggregated by category), as a
result of—

“(AA) overpayments;
“(BB) erroneous payments;
“(CC) uncashed checks or incom-
plete payments;
“(DD) billing errors;
“(EE) subrogation;
“(FF) fraud; or
“(GG) any other reason on behalf
of the covered plan.”.

(B) ANNUAL DISCLOSURE.—Clause (v) of
section 408(b)(2)(B) of such Act (29 U.S.C.
1108(b)(2)(B)), as amended by paragraph
(2)(B), is amended by adding at the end the
following:

“(IV) A covered service provider, with re-
spect to a contract or arrangement with the
covered plan in connection with providing third
party administration services for group health
plans, shall disclose, on an annual basis not
later than 60 days after the beginning of the
current plan year, to a responsible plan fidu-
ciary, in writing, the following with respect to
the twelve months preceding the current plan
year:

“(aa) All direct compensation de-
scribed in subclause (III) of clause (iii).

“(bb) All indirect compensation de-
scribed in subclause (IV) of clause (iii) re-
ceived by the covered service provider, an
affiliate, or a subcontractor (including such
compensation described in subclause (VIII)
of clause (iii)).

“(cc) The aggregate amount for which
the covered service provider, an affiliate, or
a subcontractor received indirect com-
pensation and the estimated amount of
cost-sharing incurred by plan participants
and beneficiaries as a result.

“(dd) The total gross spending by the
covered plan on all costs and fees arising
under or paid under the administrative
services agreement with the covered service
provider (not including any amounts de-
scribed in items (aa) through (cc) of clause
(iii)(VIII)).
“(ee) The total net spending by the covered plan on all costs and fees arising under or paid under the administrative services agreement with the covered service provider.

“(ff) The aggregate fees collected by the covered service provider, an affiliate, or a subcontractor.

“(gg) Any other information specified by the Secretary through regulations or guidance that may be necessary for a responsible plan fiduciary to consider the merits of the contract or arrangement with the covered service provider and any conflicts of interest that may exist.”.

(C) THIRD PARTY ADMINISTRATION SERVICES FOR GROUP HEALTH PLANS DEFINED.—Clause (ii)(I) of section 408(b)(2)(B) of such Act (29 U.S.C. 1108(b)(2)(B)), as amended by paragraph (2)(C), is amended by adding at the end the following:

“(ii) The term ‘third party administration services for group health plans’ includes any services provided by a covered service provider, an affiliate, or a subcon-
tractor to a covered plan with respect to
the administration of health benefits under
the covered plan, including—

“(AA) the processing, repricing,
and payment of claims;

“(BB) design, creation, and
maintenance of provider networks;

“(CC) negotiation of discounts
off gross rates;

“(DD) benefit and plan design;

“(EE) negotiation of payment
rates;

“(FF) recordkeeping;

“(GG) utilization review;

“(HH) adjudication of claims;

“(II) regulatory compliance; and

“(JJ) any other services set forth
in an administrative services agree-
ment or similar agreement or specified
by the Secretary through rule-
making.”.

(4) RULE OF CONSTRUCTION.—Nothing in the
amendments made by this section shall be construed
to imply that a practice in relation to which a cov-
ered service provider is required to provide informa-
tion as a result of such amendments is permissible under Federal law.

(5) **Effective Date.**—No contract or arrangement entered into prior to January 1, 2025, shall be subject to the requirements of subsection (b).

(e) **Implementation.**—Not later than 1 year after the date of enactment of this Act, the Secretary of Labor shall issue notice and comment rulemaking as necessary to implement the provisions of this section. The Secretary shall ensure that such rulemaking—

(1) accounts for the varied compensation practices of covered service providers (as defined under section 408(b)(2)(B); and

(2) establishes standards for the disclosure of expected compensation by such covered service providers.

**Sec. 403. Prescription Drug Price Information Requirement.**

(a) **PHSA.**—

(1) **In General.**—Part D of title XXVII of the Public Health Service Act, as amended by section 106, is further amended by adding at the end the following new section:
“SEC. 2799A–12. INFORMATION ON PRESCRIPTION DRUGS.

“(a) IN GENERAL.—A group health plan or a health insurance issuer offering group or individual health insurance coverage shall—

“(1) not restrict, directly or indirectly, any pharmacy that dispenses a prescription drug to an enrollee in the plan or coverage from informing (or penalize such pharmacy for informing) an enrollee of any differential between the enrollee’s out-of-pocket cost under the plan or coverage with respect to acquisition of the drug and the amount an individual would pay for acquisition of the drug without using any group health plan or health insurance coverage; and

“(2) ensure that any entity that provides pharmacy benefits management services under a contract with any such health plan or health insurance coverage does not, with respect to such plan or coverage, restrict, directly or indirectly, a pharmacy that dispenses a prescription drug from informing (or penalize such pharmacy for informing) an enrollee of any differential between the enrollee’s out-of-pocket cost under such plan or coverage with respect to acquisition of the drug and the amount an individual would pay for acquisition of the drug
without using any group health plan or health insurance coverage.

“(b) DEFINITION.—For purposes of this section, the term ‘out-of-pocket cost’, with respect to acquisition of a drug, means the amount to be paid by the enrollee under the plan or coverage, including any cost-sharing (including any deductible, copayment, or coinsurance) and, as determined by the Secretary, any other expenditure.’’

(2) CONFORMING AMENDMENT.—Section 2729 of the Public Health Service Act (42 U.S.C. 300gg–29) is amended by adding at the end the following new subsection:

“(c) SUNSET.—The preceding provisions of this section shall not apply beginning on the date of the enactment of this subsection.”.

(b) ERISA.—

(1) IN GENERAL.—Subpart B of part 7 of Subtitle B of title I of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1185 et seq.), as amended by section 106, is further amended by adding at the end the following new section:

“SEC. 727. INFORMATION ON PRESCRIPTION DRUGS.

“(a) IN GENERAL.—A group health plan or a health insurance issuer offering group health insurance coverage shall—
“(1) not restrict, directly or indirectly, any pharmacy that dispenses a prescription drug to a participant or beneficiary in the plan or coverage from informing (or penalize such pharmacy for informing) a participant or beneficiary of any differential between the participant’s or beneficiary’s out-of-pocket cost under the plan or coverage with respect to acquisition of the drug and the amount an individual would pay for acquisition of the drug without using any group health plan or health insurance coverage; and

“(2) ensure that any entity that provides pharmacy benefits management services under a contract with any such health plan or health insurance coverage does not, with respect to such plan or coverage, restrict, directly or indirectly, a pharmacy that dispenses a prescription drug from informing (or penalize such pharmacy for informing) a participant or beneficiary of any differential between the participant’s or beneficiary’s out-of-pocket cost under such plan or coverage with respect to acquisition of the drug and the amount an individual would pay for acquisition of the drug without using any group health plan or health insurance coverage.
“(b) DEFINITION.—For purposes of this section, the term ‘out-of-pocket cost’, with respect to acquisition of a drug, means the amount to be paid by the participant or beneficiary under the plan or coverage, including any cost-sharing (including any deductible, copayment, or coinsurance) and, as determined by the Secretary, any other expenditure.”.

(2) CLERICAL AMENDMENT.—The table of contents in section 1 of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1001 et seq.), as amended by section 106, is further amended by inserting after the item relating to section 726 the following new item:

“Sec. 727. Information on prescription drugs.”.

(c) IRC.—

(1) IN GENERAL.—Subchapter B of chapter 100 of the Internal Revenue Code of 1986, as amended by section 106, is further amended by adding at the end the following:

“SEC. 9827. INFORMATION ON PRESCRIPTION DRUGS.

“(a) IN GENERAL.—A group health plan shall—

“(1) not restrict, directly or indirectly, any pharmacy that dispenses a prescription drug to a participant or beneficiary in the plan from informing (or penalize such pharmacy for informing) a participant or beneficiary of any differential between the
participant’s or beneficiary’s out-of-pocket cost under the plan with respect to acquisition of the drug and the amount an individual would pay for acquisition of the drug without using any group health plan or health insurance coverage; and

“(2) ensure that any entity that provides pharmacy benefits management services under a contract with any such plan does not, with respect to such plan or coverage, restrict, directly or indirectly, a pharmacy that dispenses a prescription drug from informing (or penalize such pharmacy for informing) a participant or beneficiary of any differential between the participant’s or beneficiary’s out-of-pocket cost under the plan with respect to acquisition of the drug and the amount an individual would pay for acquisition of the drug without using any group health plan or health insurance coverage.

“(b) DEFINITION.—For purposes of this section, the term ‘out-of-pocket cost’, with respect to acquisition of a drug, means the amount to be paid by the participant or beneficiary under the plan, including any cost-sharing (including any deductible, copayment, or coinsurance) and, as determined by the Secretary, any other expenditure.”.

(2) CLERICAL AMENDMENT.—The table of sections for subchapter B of chapter 100 of the Inter-
inal Revenue Code of 1986, as amended by section
106, is further amended by adding at the end the
following new item:

“Sec. 9827. Information on prescription drugs.”.

**SEC. 404. IMPLEMENTATION FUNDING.**

(a) IN GENERAL.—For the purposes described in
subsection (b), and in addition to amounts otherwise avail-
able for such purposes there are appropriated, out of
amounts in the Treasury not otherwise appropriated, to
the Secretary of Labor $12,000,000, for fiscal year 2024,
to remain available through fiscal year 2029.

(b) PERMITTED PURPOSES.—The purposes described
in this subsection are limited to the following purposes,
insofar as such purposes are to carry out the provisions
of, including the amendments made by, title I and IV:

(1) Preparing, drafting, and issuing proposed
and final regulations or interim regulations.

(2) Preparing, drafting, and issuing guidance
and public information.

(3) Preparing, drafting, and publishing reports.

(4) Enforcement of such provisions.

(5) Reporting, collection, and analysis of data.

(6) Other administrative duties necessary for
implementation of such provisions.

(c) TRANSPARENCY OF IMPLEMENTATION FUNDS.—
The Secretary described in subsection (a) shall annually
submit, no later than September 1st of each year, to the Committees on Education and Workforce and on Appropriations of the House of Representatives and the Committees on Health, Education, Labor, and Pensions and on Appropriations of the Senate a report on funds expended pursuant to funds appropriated under this section.